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Described as one of the costliest and most debilitating disorders, schizophrenia has proven to 
be among the greatest challenges for medical researchers.  The disorder poses difficulties on 
all levels: from genotype to phenotype.  Even though it is known that there is a substantial 
genetic contribution to schizophrenia susceptibility (~80%), it is unknown whether this is due 
to common variants, rare variants, epigenetic factors, polymorphisms in regulatory regions of 
the genome or a combination of all these factors.  Over the past few decades, many 
approaches have been employed to elucidate the genetic architecture of schizophrenia, with 
the latest and most promising being genome wide association studies (GWAS).  However, 
nearly a decade after the first GWAS, the limitations are increasingly being recognised and 
new avenues need to be explored.  Studies have recently started to focus on the analysis of 
non-coding regions of the genome since these regions harbour the majority of variants 
identified in GWAS thus far. 
This study aimed to use recently developed programs that utilize data from large scale studies 
such as previous GWAS, the Encyclopaedia of DNA Elements (ENCODE), 1000 Genomes, 
HapMap and Functional Annotation of the Mammalian Genome (FANTOM) to establish a 
simple, yet effective bioinformatics pipeline for the identification and assessment of variants 
in regulatory regions.  Using the established workflow, 149 single nucleotide polymorphisms 
(SNPs) in regulatory regions were implicated in schizophrenia susceptibility, with the most 
significant SNP being rs200981.  Pathway and network analysis using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) and GeneMANIA respectively 
indicated that the most frequently affected genes were involved in immune responses or 
neurodevelopmental processes, which support previous findings.  Yet, novel findings of this 
study implicated processes crucial for DNA packaging (from DNA level to chromatin level).   
The second part of the study used restriction fragment length polymorphism analysis of 
polymerase chain reaction-amplified fragments (PCR-RFLP) to genotype ten of the most 
significant SNPs (identified by bioinformatic analyses in the first part of the study) in a South 
African Xhosa cohort of 100 cases and 100 controls, while bi-directional Sanger sequencing 
was used to confirm the presence of these SNPs.  Statistical analyses revealed two haplotypes 
of regulatory variants, rs200483-rs200485-rs2517611 (p = 0.0385; OR = 1.71; 95% CI = 
1.01-2.91) and rs200981-rs2517611-rs3129701 (p = 0.041; OR = 0.51; 95% CI = 0.27-0.98) 
associated with schizophrenia susceptibility.  Bioinformatic analysis indicated that these 
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haplotypes affect DNA packaging, which supported the findings of the first part of the study 
and could implicate epigenetic processes. 
The findings of this study support the importance of regulatory variants in schizophrenia 
susceptibility.  This study also showed the importance of combining GWAS data with 
additional analyses in order to better understand complex diseases.  It is hoped that these 
findings could fuel future research, specifically in genetically unique populations. 
 




Skisofrenie kan beskryf word as een van die duurste en mees ernstige siektes en bly steeds 
een van die grootste uitdagings vir mediese navorsers.  Hierdie versteuring behels probleme 
op alle vlakke: van genotipe tot fenotipe.  Alhoewel dit bekend is dat daar 'n aansienlike 
genetiese bydrae tot skisofrenie vatbaarheid is (~ 80%), is dit onbekend of dit is as gevolg 
van algemene variasies, skaars variasies, epigenetiese faktore, variasies in regulerende 
gebiede van die genoom of 'n kombinasie van al hierdie faktore.  Oor die afgelope paar 
dekades is verskeie benaderings gebruik om die genetiese samestelling van skisofrenie te 
bestudeer, met die nuutste en mees belowende synde genoom-wye assosiasie studies 
(GWAS).  Byna 'n dekade na die eerste GWAS, word die beperkinge egter toenemend erken 
en nuwe navorsingstrategieë moet gebruik word.  Studies het onlangs begin om meer te fokus 
op die analise van nie-koderende areas van die genoom aangesien hierdie areas die 
meerderheid van die variasies behels wat tot dusver in GWAS geïdentifiseer is.  
Hierdie studie het gepoog om onlangs ontwikkelde programme, wat gebruik maak van die 
data van grootskaalse studies soos vorige GWAS, die “Encyclopaedia of DNA Elements” 
(ENCODE), “1000 Genomes”, “HapMap” en “Functional Annotation of the Mammalian 
Genome” (FANTOM), te implementeer om sodoende 'n eenvoudige, maar doeltreffende 
bioinformatika pyplyn vir die identifisering en evaluering van variante in regulerende 
gebiede, te vestig.  Deur die gebruik van die gevestigde bioinformatika pyplyn, is 149 enkel 
nukleotied polimorfismes (SNPs) in regulerende gebiede in skisofrenie vatbaarheid betrek, 
met rs200981 wat die mees betekenisvol was.  Pad- en netwerk-analise met die 
onderskeidelike hulp van die “Database for Annotation, Visualization and Integrated 
Discovery” (DAVID) en “GeneMANIA”, het aangedui dat die gene wat die meeste 
geaffekteer was, betrokke is by immuunreaksies en neuro-ontwikkeling.  Hierdie bevindinge 
ondersteun vorige studies.  Tog het nuwe bevindinge van hierdie studie prosesse geïmpliseer 
wat uiters noodsaaklik is vir DNS verpakking (van DNS- tot chromatien-vlak). 
Die tweede deel van die studie het restriksie fragment lengte polimorfisme analise van 
polimerase ketting reaksie geamplifiseerde fragmente (PKR-RFLP) gebruik om tien van die 
belangrikste SNPs (wat geïdentifiseer is deur bioinformatiese ontledings in die eerste deel 
van die studie) in `n Suid-Afrikaanse Xhosa studiegroep van 100 skisofrenie gevalle en 100 
kontroles te genotipeer, terwyl tweerigting Sanger volgordebepaling gebruik is om die 
teenwoordigheid van hierdie SNPs te bevestig. Statistiese analise het aangedui dat twee 
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haplotipes van regulerende variante, rs200483-rs200485-rs2517611 (p = 0.0385; OR = 1.71; 
95% CI = 1.01-2.91) en rs200981-rs2517611-rs3129701 (p = 0.041; OR = 0.51; 95% CI = 
0.27-0.98), geassosieer is met skisofrenie vatbaarheid.  Bioinformatiese analise het aangedui 
dat hierdie haplotipes DNS verpakkingsprosesse affekteer, wat die bevindinge van die eerste 
deel van hierdie studie ondersteun en moontlik epigenetiese prosesse impliseer. 
Die bevindinge van hierdie studie ondersteun die belangrikheid van regulerende variante in 
skisofrenie vatbaarheid.  Hierdie studie het ook bewys hoe belangrik dit is om GWAS data 
met addisionele analises te kombineer om sodoende komplekse siektes beter te verstaan.  
Daar word gehoop dat hierdie resultate tot meer studies in die toekoms sal lei, spesifiek in 
genetiese unieke bevolkings. 
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The initial definition of the central dogma of molecular biology seemed simple: DNA 
encodes for RNA, which in turn encodes proteins.  However, since this definition was first 
articulated by Francis Crick in 1958 (Crick, 1958 as cited in Crick 1970), it has become 
known that gene expression involves many more factors than previously thought.  For 
example, the non-coding genome which was first considered “junk DNA” is now considered 
to have a significant role in gene regulation and expression (Ward & Kellis, 2012).  This has 
significant implications for the way in which research studies should be designed, performed 
and interpreted, particularly regarding complex diseases. 
One such a complex disorder is schizophrenia.  Genetic predisposition to the disorder is 
supported by the prevalence of schizophrenia among related individuals, with heritability 
estimates as high as 80% (Girard et al., 2011).  The incidence of schizophrenia in the general 
population is approximately 1%, while this percentage increases significantly between 
relatives (Gottesman & Shields, 1967).  The genetic contribution to this disorder became 
apparent during the 1960’s (Heston, 1966), which fuelled the search for a candidate gene 
involved in schizophrenia.  While many linkage and candidate gene studies successfully 
associated a number of variants in/near genes associated with the disorder, it eventually 
became clear that there is not merely one variant associated with the disorder.  According to 
the SchizophreniaGene/SZGene Database (June 2014, www.szgene.org), more than 1 700 
studies regarding schizophrenia have been completed, in which 1008 genes and 8 788 
polymorphisms have been researched.  There are three key points that should be remembered 
with these numbers: firstly, not all findings were significant and many of the findings to date 
have only been replicated once or not at all; the studies tend to rely on small sample sizes and 
finally, due to technological or financial restraints, only a few markers were assessed for each 
gene (Kim et al., 2011).  In 2005, the first successful GWAS was performed (Klein et al., 
2005) and opened the doors for a new hypothesis free approach in schizophrenia research.  
Though many significant variants have been identified in a number of large GWAS, the 
pitfalls and gaps of these studies have lead researchers to start looking toward additional 
avenues to explore.  While GWAS explore the whole genome and is effective in identifying 
common variants with small effect sizes, this does not include rare variants with large effect 
sizes, nor epigenetic factors (Korte & Farlow, 2013).  Furthermore, many of the identified 
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common variants occur in non-coding regions – a part of the genome that has until recently 
been very rarely explored.  However, in order to effectively study the way in which genetic 
factors are involved in complex diseases, researchers are starting to realise the potential of 
including functional interpretation of regulatory variation in association studies (Gaffney, 
2013). 
The release of ENCODE data has made it significantly easier to study non-coding regions of 
the human genome (The ENCODE Project Consortium, 2012).  In September 2003 this 
project was launched by the United States National Human Genome Research Institute 
(NHGRI), with the primary goal of unravelling the non-coding genome and characterizing 
functional elements.  Nine years and approximately $400 million later, the ENCODE findings 
spanned a staggering 57 pages in the September 2012 issue of Nature (Volume 489, Issue 
7414) alone.  The amount of data generated by more than 1800 genome-wide experiments 
was equivalent to the amount obtained if the human genome had to be sequenced 1700 times.  
Despite these surreal figures, this is still just the beginning.  For example, only a mere 10% of 
the estimated 1400 human transcription factors were analysed with chromatin 
immunoprecipitation sequencing (ChIP-Seq) data (Dunham, 2013).  
With the advent of next generation sequencing techniques and large projects such as that of 
the ENCODE consortium, vast amounts of data are continuously being generated.  Yet, 
instead of an increased understanding of the genetic mechanisms underlying many diseases, 
this has led to a research bottleneck.  According to Curtis (2013), no next generation 
sequencing results can be interpreted as biologically meaningful without being followed up.  
Some of the ways that these results can be of value are by mining variant databases, 
evaluating the biological consequences and replicating findings of previous studies.  
Consequently, there is still an immense amount of research that needs to be performed in 
order to address many biological questions.  This suggests that research focus should be 
adjusted from data generation to data mining and thorough analysis.  By combining the 
findings of projects such as ENCODE and FANTOM, 5
th
 Edition (FANTOM5) with what is 
already known about the genetic architecture of the human genome, this could provide clues 
to unravelling the intricate networks involved in complex disorders, such as schizophrenia. 
The urgency to resolve the genetic complexity of schizophrenia is due to the heavy burden of 
this disorder on the affected individuals, caregivers and communities.  This is even worse in 
developing countries and it has been estimated that between 4 and 5 million African 
Stellenbosch University  http://scholar.sun.ac.za




individuals suffer from some form of psychiatric disorder (Purgato et al., 2012).  The most 
recent statistics available for mental health in the South African population (released in 
2008), indicated that approximately 30% of South African individuals suffer from some form 
of psychiatric illness (Stein et al., 2008) and that neuropsychiatric disorders are third only to 
HIV/AIDS and infectious diseases  in terms of the national burden of diseases (Seedat et al., 
2009). However, while HIV/AIDS is considered an epidemic and receives a considerable 
amount of time and money which is dedicated to research and treatment, neuropsychiatric 
disorders lag behind severely (Lund et al., 2010).   
Taking these factors into account, it seems rather tragic that despite modern technology and 
the research efforts that are being put forth around the world, there is still no cure or effective 
treatment for schizophrenia.  Therefore, by using novel strategies and the multitude of 
available data as described in this study, it is hoped that clues can be provided to aid in the 
elucidation of the complex genetic architecture of this disorder. 
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2.1 SCHIZOPHRENIA: THE DISORDER 
2.1.1 General description and a brief history 
The Diagnostic and Statistical Manual of Mental Disorders V (DSM-V, American Psychiatric 
Association, 2013) defines schizophrenia as a debilitating mental disorder characterized by 
disturbances in behaviour and cognition.  This disorder affects approximately 24 million 
people worldwide (World Health Organisation, 2013), with no signs of decreasing 
incidences.  
Schizophrenia was first described in the late nineteenth century by German psychiatrist Emil 
Kraepelin (1856-1926) as “dementia praecox” which translates to “dementia of the young” 
(Walker et al., 2004).  This name was very much representative of what is still true today: 
onset of the illness is commonly observed between the ages of 20 and 25.  Kraepelin also 
described subtypes of the disorder such as “paranoid”, “catatonic” and “hebephrenic” 
(disorganised) schizophrenia, but it was clear from the beginning that diagnosis of the 
disorder would be difficult.  By the early twentieth century, the more modern term 
“schizophrenia” was proposed by Eugen Bleuler (1857-1939).  This term is derived from the 
Greek “schizo” and “phren” which means “to split” and “mind” respectively (Walker et al., 
2004).  Therefore, by definition, schizophrenia means that there is a split in the mind of an 
individual suffering from the disorder, which directly relates to the DSM-V definition of 
disruptions in cognition.  However, this description of a split mind has often been 
misunderstood by those that are unfamiliar with the disorder as a split personality disorder, 
which is incorrect.  Even though Bleuler classified symptoms such as hallucinations, 
delusions, depression and mania as indicators of schizophrenia, he also stated that these 
symptoms overlapped with other mental illnesses.  This had a significant influence on the 
diagnosis of the disorder.  Furthermore, he labelled the broad range of symptoms with 
varying severity as the “group of schizophrenias”, which is reflective of the highly 
heterogeneous nature of the disorder today (Bleuler, 1911 as cited in Walker et al., 2004).  
Nonetheless, the description of schizophrenia that has probably had the most significant 
impact on diagnosis was given by Kurt Schneider in 1959.  He defined key symptoms of 
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schizophrenia which mainly distinguished between different types of hallucinations and 
delusions (e.g. thought broadcasting, thought echoing, thought withdrawal and thought 
intrusion).   
Despite the fact that these descriptions of schizophrenia date back to more than a century, the 
illness still remains poorly understood (Tandon et al., 2008).  Statistics indicate that it is the 
third most debilitating disorder, relative to other mental, neurological and substance abuse 
disorders (Collins et al., 2011).  Furthermore, schizophrenia has been estimated to decrease 
an affected individuals’ life expectancy by 10 to 15 years due to a myriad of accompanying 
problems such as health issues and an increased likelihood to commit suicide (Sullivan et al., 
2012; Mowry & Gratten, 2013).  Due to the burden of the disorder as well as the depression 
that often accompanies it, suicide attempts are estimated to be at 50%, while 7-10% of the 
individuals succeed (American Psychiatric Association, 2013). 
The devastating effects of schizophrenia extend far beyond the affected individual; it is a 
psychological, socio-economic and family burden.  Furthermore, diagnosis is problematic 
and no specific biomarkers have been identified to date.  The disorder also appears to have an 
obscure pathogenesis and treatment tends to be ineffective (Cacabelos, 2013).  The economic 
implications are mainly due to factors such as health complications, disability, destitution, 
and low employment rates (Mowry & Gratten, 2013).  As mentioned previously, 
schizophrenics find it difficult to secure employment and will usually require some sort of 
assistance from family or friends. 
Even though there are no exact measures of the burden of schizophrenia, a good indication of 
the financial burden is provided by a 2012 report by the Personal Social Services Research 
Unit at the London School of Economics which estimated the yearly costs in the United 
Kingdom to be £11.8 billion (Knapp et al., 2004).  This is due to a number of direct costs 
(e.g. inpatient treatment and medication) and indirect costs (e.g. due to job loss, 
homelessness, expenses of caregivers), making it one of the most expensive mental disorders 
worldwide (Rössler et al., 2005).  Furthermore, according to Lauber et al. (2005), if the time 
and effort of primary caregivers could be converted to a monetary unit this amount would 
equal the costs of inpatient treatment.  
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2.1.2 Symptoms, onset & diagnosis 
Delusions, hallucinations, bizarre behaviour and disordered speech are often part of the 
diverse symptoms that an individual can exhibit (American Psychiatric Association, 2013); 
however diagnosis is complicated not only by the range of these symptoms, but also by the 
severity of the symptoms.   
Distinctions between negative, positive and general symptoms have only been made since the 
late 1980’s (Harvey & Walker, 1987).  Positive symptoms are usually an exaggeration of 
normal functions such as hallucinations, delusions and grandiosity, while negative symptoms 
are synonymous with loss of normal functions which manifest as emotional and social 
withdrawal and a lack of spontaneity.  Finally, general psychopathological symptoms include 
anxiety, tension, depression and uncooperativeness, to name a few (American Psychiatric 
Association, 2013).  In addition to the broad range of symptoms associated with 
schizophrenia, the severity of these symptoms can vary and are measured by a multitude of 
scales such as the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987), the 
Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1962), Scale for the Assessment 
of Negative Symptoms (SANS) and Scale for the Assessment of Positive Symptoms (SAPS; 
Andreasen, 1990).  These scales provide a comprehensive means of assessing schizophrenia 
symptoms, which is fundamental for the accurate diagnoses of disorders comprising a 
continuous range of clinical symptoms (Niehaus et al., 2005).  SANS and SAPS were used to 
measure symptom severity in the South African Xhosa cohort used in this study (Chapter 4).  
SANS can be divided into five subgroups of negative symptoms, namely affective blunting, 
anhedonia/asociality, lack of attention, avolition/apathy and alogia.  Similarly, SAPS can be 
divided into four subgroups of positive symptoms, namely delusions, hallucinations, bizarre 
behaviour and formal though disorder.  Each of the subgroups is then rated on a scale 
between 0 (absent) and 5 (severe) (Andreasen, 1990). 
Today, the DSM-V (American Psychiatric Association, 2013) is most commonly used as a 
guideline for licenced health officials to diagnose individuals who suffer from schizophrenia.  
However, there are alternative diagnostic systems such as the International Classification of 
Diseases (ICD-10).  The criteria used for diagnosis according to the DSM-V are summarised 
in Table 2.1.   
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 2  LITERATURE REVIEW  
8 
 
Table 2.1. Diagnostic criteria for schizophrenia (DSM-V, American Psychiatric 
Association, 2013) Reprinted with permission from the Diagnostic and Statistical Manual 
of Mental Disorders, Fifth Edition, (Copyright 2013). American Psychiatric Association. 
A. 
Two (or more) of the following, each present for a significant portion of time during a 
one month period (or less if successfully treated). At least one of these must be (1 ), 
(2), or (3): 
1. Delusions. 
2. Hallucinations. 
3. Disorganized speech (e.g., frequent derailment or incoherence). 
4. Grossly disorganized or catatonic behaviour. 
5. Negative symptoms (i.e., diminished emotional expression). 
 
B.  
For a significant portion of the time since the onset of the disturbance, level of 
functioning in one or more major areas, such as work, interpersonal relations, or self-
care, is markedly below the level achieved prior to the onset (or when the onset is in 
childhood or adolescence, there is failure to achieve expected level of interpersonal, 
academic, or occupational functioning). 
 
C.  
Continuous signs of the disturbance persist for at least 6 months. This 6-month period 
must include at least 1 month of symptoms (or less if successfully treated) that meet 
Criterion A (i.e., active-phase symptoms) and may include periods of prodromal or 
residual symptoms. During these prodromal or residual periods, the signs of the 
disturbance may be manifested by only negative symptoms or by two or more 




Schizoaffective disorder and depressive or bipolar disorder with psychotic features 
have been ruled out because either 1 ) no major depressive or manic episodes have 
occurred concurrently with the active-phase symptoms, or 2) if mood episodes have 
occurred during active-phase symptoms, they have been present for a minority of the 
total duration of the active and residual periods of the illness. 
 
E.  
The disturbance is not attributable to the physiological effects of a substance (e.g., a 
drug of abuse, a medication) or another medical condition. 
 
F.  
If there is a history of autism spectrum disorder or a communication disorder of 
childhood onset, the additional diagnosis of schizophrenia is made only if prominent 
delusions or hallucinations, in addition to the other required symptoms of 
schizophrenia, are also present for at least 1 month (or less if successfully treated). 
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Even though the prevalence of schizophrenia is more or less equal between male and female 
individuals, males tend to have an earlier onset of the disorder as well as a more debilitating 
course of the illness (American Psychiatric Association, 2013).  Onset is usually observed in 
late teenage or early adult years; however there are cases of individuals showing symptoms 
much earlier or later on.  According to the DSM-V, onset can be preceded by a “pre-morbid 
personality” during which an individual may exhibit unusual behaviour, whereas other 
individuals might appear completely normal before experiencing their first psychotic episode.  
It is, however, more likely that onset of initial clinical symptoms will be preceded by 
increasingly bizarre behaviour and that there would have been subtle signs of the disorder as 
early as childhood (American Psychiatric Association, 2013). 
 
2.1.3 Treatment 
Even though there is currently no cure for schizophrenia, treatment regimens to alleviate 
symptoms are available.  Nonetheless, it has been estimated that more than 50% of affected 
individuals are not receiving appropriate treatment (World Health Organisation, 2013). More 
than 74% of patients do not fully adhere to treatment regimens, which may be attributed in 
part to adverse drug reactions (ADRs), and relapse rates are extremely high as a result of the 
ineffective antipsychotics currently available (Mowry & Gratten, 2013).  In a study 
completed by Lieberman et al. (2005), 74% of individuals, in a cohort of 1 493 American 
schizophrenia patients (including Caucasian, Indian, Alaska Native, Asian and Native 
Hawaiian individuals as well as individuals of mixed race), did not complete antipsychotic 
treatment due to intolerable ADRs or inefficacy of the antipsychotics prescribed.  The 
individuals received one of five different antipsychotic drugs for a period of 18 months.  The 
medication with the lowest discontinuation rates was Olanzapine; however it was also 
associated with greater weight gain and altered lipid and glucose metabolism, which 
emphasizes the limited effectiveness of these medications.  It is therefore vitally important to 
improve existing antipsychotic medication.   
Schizophrenia is most commonly treated with two main classes of antipsychotic medication: 
first generation and second generation antipsychotics (Xu et al., 2013).  First generation 
antipsychotics emerged in the 1950s and are more effective in the treatment of positive 
symptoms (Tandon et al., 2010).  These agents act by blocking dopamine receptors, thereby 
reducing dopamine activity.  However, ADRs induced by these medications can easily occur 
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and can be more debilitating than schizophrenia itself.  The main side-effect comprises 
disturbances within motor control and can result in tardive dyskinesia (TD), 
pseudoparkinsonism, restlessness and dystonia.  Even though symptoms such as 
parkinsonism could be reversible, TD and dystonia last much longer and cannot always be 
alleviated (Arranz & De Leon, 2007).  TD, specifically, occurs in a staggering 20-30% of 
patients who are treated with first-generation antipsychotics (Srivastava et al., 2006).  Due to 
the harmful effects associated with these first-generation antipsychotics, psychiatrists have 
opted for second-generation antipsychotics which target a number of different 
neurotransmitter receptors and can be used for the treatment of positive as well as negative 
symptoms (Lieberman et al., 2005).  Even though second-generation antipsychotics are 
particularly effective in the treatment of drug-resistant schizophrenia with motor side-effects 
being a less frequent ADR, other major side-effects can still occur, such as metabolic 
syndrome, weight gain, cardiomyopathies and agranulocytosis (Cacabelos et al., 2011; 
Meltzer, 2012).  In addition to antipsychotic treatment, patients may undergo psychotherapy 
or cognitive-behavioural therapy, but more often than not, individuals will have to be 
admitted to a hospital for treatment.  Treatment can result in relatively brief periods of 
remission, however this is a lifelong disorder characterised by fluctuations in a declining 
mental state (Tandon et al., 2009). 
Despite the fact that schizophrenia is a complex disorder, patients are initially treated 
according to a standardized regimen which does not always account for the broad 
heterogeneity of the condition.  The type and dosage of medication is then gradually adjusted 
to suit an individual as far as possible, based on their response to a medication up to that 
point (Müller et al., 2013).  Taking into consideration the heterogeneous nature of 
schizophrenia as well as variable treatment response and the number of antipsychotics that 
are available today, this is no easy task (Tandon et al., 2010).  Therefore, by understanding 
the aetiology of schizophrenia and the genetics involved in antipsychotic response, the cost 
and time to optimize treatment and reduce ADRs can possibly be eliminated.   
The field of pharmacogenetics / pharmacogenomics actively researches alternatives to the 
current failing system of treatment in schizophrenia and aims to move toward personalised 
medicine (Zandi & Judi, 2010).  Treatment tailored for the individual patient will not only 
alleviate the symptoms of schizophrenia, but could potentially eliminate ADRs.  However, 
progress in the pharmacogenetic research of schizophrenia is hindered by the current lack in 
knowledge of the underlying mechanisms that contribute to the clinical manifestation of the 
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disorder (Cacabelos et al., 2011).  This obstacle is increasingly being acknowledged, with 
many major pharmaceutical companies opting to move away from traditional drug-focused 
research to understanding disease aetiology (Mowry & Gratten, 2013).    
 
2.1.4 Aetiology 
The aetiology of schizophrenia remains poorly understood.  It is generally accepted that 
schizophrenia is a neurodevelopmental disorder and furthermore that the clinical 
manifestations observed are as a result of both genetic and environmental factors (Williams et 
al., 2009).  Various chemical and anatomical changes have been observed in affected 
individuals, including impaired cortical structures, ventricular enlargement and altered 
chemical receptors (Stachowiak et al., 2013).  Due to disorder complexity and insufficient 
information regarding the mechanism underlying prognosis, a number of hypotheses have 
been proposed: neurodevelopmental defects, the polygenic inheritance model, perinatal 
epigenetic effects, immune dysfunction, seasonal infection and finally, dysfunctions of a 
number of chemical receptors including the dopamine, choline, serotonin, gamma-
aminobutyric acid (GABA) and N-methyl-D-aspartate (NMDA) receptors (Cacabelos, 2013). 
Pedigree analyses have indicated that schizophrenia is inherited in a non-Mendelian manner 
(Tandon et al., 2008).  The complexity of schizophrenia is highlighted by the myriad of loci 
that have been identified by linkage and candidate gene association studies, however, it is 
suspected that the majority of genes involved in the disorder are yet to be identified (Girard et 
al., 2011).  Based on the plethora of studies and the inability to replicate many of the 
findings, it is unlikely that one or a few genetic polymorphisms are responsible for 
schizophrenia susceptibility.  It is expected that multiple variants in numerous genes are 
involved - potentially hundreds or thousands of variants (Harrison & Weinberger, 2005; 
Curtis, 2013).  Furthermore, this hypothesis is supported by the major overlaps between the 
symptoms (and in some instances common genetic variants) of schizophrenia and other 
mental disorders such as autism and bipolar disorder (Gejman et al., 2011; Cross-Disorder 
Group of the Psychiatric Genomics Consortium, 2013).  This indicates that there is not one 
causal variant specific to one disorder, but rather a complex network of common variants that 
contribute to complex phenotypes associated with different disorders.  Alternatively, there is 
also the possibility that individual variants such as copy number variants (CNVs) could have 
a substantial effect on disease aetiology.  CNVs are duplications or deletions of genomic 
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segments ranging between 1 kb to several million bases in length (Cantor & Geschwind, 
2008), and may be very rare (p << 0.01) (Haraldsson et al., 2011; Curtis, 2013).  Not only 
does the surfeit of expected associated polymorphisms complicate diagnosis of 
schizophrenia, but also the ability to develop effective treatments.   
 
Figure 2.1.  Allelic spectrum of schizophrenia.  Common variants with small effect size are 
indicated toward the lower right corner of the graph (the red and yellow circles), while rare 
variants with a substantial effect are indicated toward the upper left corner of the graph (the 
light blue diamonds). As the risk allele prevalence increases, the genotypic relative risk of the 
allele decreases. (Figure adapted from Kim et al., 2011; Sullivan et al., 2012.) Reprinted with 
permission from Oxford University press and Nature Publishing Group. 
 
These two abovementioned hypotheses, namely the common disease – common variant 
(CDCV) and common disease – rare variant (CDRV) hypothesis, are at opposite ends of the 
spectrum (as indicated in Fig. 2.1) and there is much debate regarding the validity of both 
hypotheses (Sullivan et al., 2012).  Arguments for the common variant hypothesis include the 
extensive number identified by GWAS; believed to be sufficient enough to capture most of 
the genetic variation present in complex disorders.  Furthermore, variations in 
endophenotypes, which is commonly observed in schizophrenia, are likely due to common 
and not rare variants (Greenwood et al., 2013).  That said, the rare variant hypothesis is 
supported by the evolutionary theory that states that disease alleles should be rare, deleterious 
variants that tend to be sporadic and rare CNVs have been implicated in a number of complex 
psychiatric disorders (Gibson, 2012).  It is likely that both hypotheses are partially correct 
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and that the intricate nature of schizophrenia can be attributed to both rare and common 
variants (Owen et al., 2010; Mulle, 2012; Wright et al., 2014). 
Considering non-genetic contributors to disease, advanced paternal age, prenatal infection, 
perinatal complications, season of birth and a history of drug abuse have been implicated in 
current literature (Tandon et al., 2008; Mulle, 2012).  The mechanism in which older paternal 
age affects the risk of schizophrenia is not completely understood, but increased 
polymorphisms due to aberrant spermatogenesis has been suggested (Byrne et al., 2003).  
Potentially harmful prenatal and perinatal events include smoking during pregnancy, 
malnutrition, toxoplasmosis and viral infections such as influenza and rubella (Tandon et al., 
2008; 2009).  Although the precise mechanism of action for these factors is unclear, it is 
thought that viral infection during pregnancy leads to an irregular immune response which 
can cause disruptions in foetal brain development (Ashdown et al., 2006), while smoking and 
malnutrition causes unnecessary stress which can lead to a hyperdopaminergic state (Lipska 
et al., 1993).  Regarding the season of birth, winter births have been associated with an 
increased risk for schizophrenia.  However, as with the aforementioned environmental risks, 
this risk factor is not fully understood either (Davies et al., 2003).   
It is known that critical neurobiological and cognitive processes in the brain are influenced by 
epigenetic processes to some extent (Dempster et al., 2013) and it is likely that epigenetic 
mechanisms mediate the interaction between genetic and environmental factors involved in 
schizophrenia (Maric & Svrakic, 2012).  Numerous studies have found evidence to support 
this hypothesis.  For instance, hyper-methylation has been shown to not only be associated 
with schizophrenia (Guidotti et al., 2007), but also to significantly worsen symptoms 
(Petronijevic et al., 2008).  Furthermore, methylation patterns of the dopamine receptor D2 
gene (DRD2) were shown to differ considerably between monozygotic twins, where only one 
twin was affected by schizophrenia (Petronis et al., 2003).  Finally, it is also possible that 
histone modifications and changes in chromatin conformation could contribute to the 
downregulation of several metabolic genes (Akbarian et al., 2005).  Post-mortem analysis of 
the prefrontal cortex of 41 individuals with schizophrenia and 41 matched control individuals 
indicated that high levels of histone 3 methylation, H3-(methyl)arginine 17 (H3meR17), 
caused down-regulation of the aforementioned metabolic genes (Akbarian et al., 2005).  
However, the epigenetic role of histones in schizophrenia has not been explored to the same 
extent as with other disorders and most of the studies have only focussed on methylation 
(Dempster et al., 2013), leaving a large gap with regards to other epigenetic factors. 
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It is important to reiterate the fact that the abovementioned genetic, environmental and 
epigenetic factors are, in most cases, merely possible explanations contributing to an 
understanding of the molecular aetiology of schizophrenia and that an absolute rationale 
remains elusive.  
 
2.2 INITIAL GENETIC STUDIES 
The first landmark study to provide evidence of inheritance involved in schizophrenia was 
completed by Heston (1966).  Children with the disorder, born to parents with and without 
schizophrenia, but adopted by individuals without the disorder, were compared.  The results 
indicated that approximately 10% of children born to schizophrenic parents eventually 
developed symptoms of the illness, whilst control individuals remained asymptomatic.  
Another adoption study, wherein the biological relatives of adopted individuals were 
compared, found that the rate of schizophrenia was much higher among the biological 
relatives than the adopted relatives (Kety et al., 1976).  Together, these studies along with 
others established the hypothesis of a genetic contribution to schizophrenia.  However, the 
extent of this contribution was still unknown.  Twin studies have shown that monozygotic 
twins who share 100% of their genetic material, have a 48% risk of schizophrenia, while 
dizygotic twins who share only half of their genetic material have a much lower risk of 17% 
(Riley & Kendler, 2006).  Finally, to put the statistics into perspective, a meta-analysis of 12 
published twin studies of schizophrenia estimated the heritability of schizophrenia to be 81%, 
with an 11% environmental risk (Sullivan et al., 2003). 
The results of these landmark studies initiated the search for candidate genes associated with 
schizophrenia susceptibility.  The strongest candidates that have emerged from these studies 
are primarily involved in chemical signalling or neuronal growth and development.  Some of 
the most significant genes identified through linkage or candidate gene studies include 
disrupted in schizophrenia 1 (DISC1) on chromosome 1, catechol-O-methyltransferase 
(COMT) on chromosome 22, neuregulin 1 (NRG1) on chromosome 8 and protein 
phosphatase 1, regulatory subunit 1B (PPP1R1B) on chromosome 17 (Karayiorgou et al., 
1995; Blouin et al., 1998; Millar et al., 2000; Li et al., 2006).  A translocation breakpoint that 
disrupts DISC1 was found to co-segregate with schizophrenia in a large Scottish family 
(Millar et al., 2000), while a functional polymorphism in the COMT gene was shown to 
increase prefrontal dopamine catabolism, which impairs cognition (Egan et al., 2001).  
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Furthermore, NRG1 is expressed in the central nervous system and NRG1 mutant mice 
showed a behavioural phenotype similar to schizophrenia mouse models (Stefansson et al., 
2002), while post-mortem studies have indicated reduced expression of PPP1R1B in the 
dorsolateral prefrontal cortex of individuals with schizophrenia (Li et al., 2006).  Importantly, 
even though variations in these candidate genes might have been associated with 
schizophrenia or a subset of phenotypes associated with schizophrenia, the exact manner in 
which these variants could increase susceptibility to the disorder remains unknown in most 
cases. 
Despite the number of associated loci, only a few genes have consistently been associated 
with schizophrenia across multiple studies and populations (Guan et al., 2012) and tend to 
include genes in the major histocompatibility complex (MHC) region on chromosome 6 
(discussed in sections 2.3 and 2.4).  This is mainly due to weak statistical associations, 
limited sample sizes, samples that are ethnically heterogeneous, inability to replicate findings 
in independent studies and, most importantly, the potentially polygenic inheritance of 
schizophrenia susceptibility (Palmatier et al., 2004).  More recently, GWAS have been 
favoured to find common variants and have proven to be more successful for schizophrenia 
genetics (Kim et al., 2011; Ripke et al., 2014).   
 
2.3 GENOME WIDE ASSOCIATION STUDIES 
As opposed to hypothesis-driven candidate gene studies which have yielded inconsistent 
results for schizophrenia, GWAS have identified a number of significant and, in some cases, 
replicated associations (Collins et al., 2012; Wright, 2014).  The approach used by GWAS 
has been particularly useful in identifying causal variants, due to the fact these studies use 
technologies that take a snapshot of the entire genome, making it possible to analyse large 
numbers of randomly sampled variants (hundreds of thousands to millions) concurrently in 
numerous individuals’ genomes (Bertram, 2008; Réthelyi et al., 2013). 
Initially, GWAS struggled to identify variants associated with schizophrenia passing the 
threshold p-value (p ≤ 5x10
-8
) for genome-wide significance, due to limited sample sizes.  
This led to a number of collaborations, resulting in consortia such as the Psychiatric GWAS 
Consortium (PGC) (Ripke et al., 2011), International Schizophrenia Consortium (ISC) 
(Purcell et al., 2009) and Molecular Genetics of Schizophrenia (MGS) (Shi et al., 2009).  
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Although not all studies have found polymorphisms passing the threshold for genome-wide 
significance, there have been a number of important findings.  The consortium with the most 
significant impact on schizophrenia research has been the PCG, with three major studies 
within the last three years.  The first study, published in 2011, identified five novel loci of 
which microRNA 137 (MIR137) had the strongest association with schizophrenia.  
Interestingly, four of the other strongly associated loci, transcription factor 4 (TCF4), 
CACNA1C, CUB and sushi multiple domains 1 (CSMD1) and chromosome 10 open reading 
frame 26 (C10orf26), were predicted targets of miR-137 (Ripke et al., 2011).  The second 
GWAS performed by the PGC identified 22 susceptibility loci, of which 13 were novel 
(Ripke et al., 2013).  The most significant finding of this study was the implication of genes 
involved in calcium signalling, namely calcium channel, voltage-dependent, L type, alpha 1C 
subunit (CACNA1C), calcium channel, voltage-dependent, beta 2 subunit (CACNB2), ARP1 
actin-related protein 1 homolog A, centractin alpha (ACTR1A), cyclin M2 (CNNM2), 
troponin C type 1 (TNNC1) and calcium homeostasis modulator 1, 2 and 3 (CALHM1, 
CALHM2, CALHM3).  Additionally, the strongest SNP association occurred in the extended 
MHC region – a region that has consistently been associated with schizophrenia across 
multiple studies and populations.  Furthermore, this study emphasized the contribution of 
common variants to the disorder, with a predicted 6 300 – 10 200 SNPs possibly contributing 
to schizophrenia aetiology and accounting for at least 32% of the variance in risk (Ripke et 
al., 2013).  The most recent study by the PGC and largest in the history of psychiatric 
research, identified a staggering 108 genetic loci associated with schizophrenia, of which 83 
were novel (Ripke et al., 2014).  The most important finding of this study was the association 
of DRD2, a gene that has previously been associated with schizophrenia, particularly 
treatment response (Lencz et al., 2006).  Additional loci of importance included those 
involved in immune responses, which supported previous findings of a link between the 
immune system and schizophrenia (Ripke et al., 2014).  Other noteworthy GWAS findings to 
date include variants spanning the major histocompatibility complex (MHC) region on 
chromosome 6, as well as intronic SNPs of TCF4 and SNPs upstream of the neurogranin 
gene (NRGN) (Shi et al., 2009; Stefansson et al., 2009).  While the consistent association of 
the MHC region is in agreement with the hypothesis of an immune component in 
schizophrenia, the implication of genes such as TCF4 and NRGN support the notion of 
aberrant pathways in brain development (Stefansson et al., 2009). 
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The SNPs identified in the abovementioned studies passed the significance threshold with p-




 and as described, these SNPs are situated near genes 
involved in various important biological processes.  Therefore, even though no conclusive 
findings have been established regarding the aetiology of the disorder, the regions that have 
been identified in these studies have offered insights into the pathophysiology of 
schizophrenia (Owen et al., 2010).  Additionally, a few structural abnormalities have also 
passed the genome-wide significance threshold with duplication and deletion sizes in the 
range of 0.02 – 9 Mb including up to 49 genes at a time (Mowry & Gratten, 2013).  This 
includes genes known to have roles in neuronal development, neuroprotection or the 
regulation of proteins in neurons and once again highlights the involvement of multiple 
genes.  
Many variants that have been identified, however, were not associated with any particular 
gene(s).  This indicates the possible involvement of variants situated outside of the coding 
region of protein-coding genes and warrants further attention to the non-coding regions of the 
genome. 
 
2.4 THE NON-CODING GENOME 
When considering the significance of the non-coding genome, there are a few facts that 
should be kept in mind.  Firstly, the roles of non-coding transcripts are increasingly being 
recognised in RNA processing and gene regulation; sequence comparisons among species 
have indicated several non-coding transcripts that are highly conserved pointing toward 
functionality of these transcripts and finally, many variants in non-coding regions have been 
implicated in a variety of disorders (Alexander et al., 2010).  Therefore, even though it has 
been long thought that 99% of the genome was simply “junk DNA”, it has become increasing 
clear that some of these non-protein coding sequences have critical regulatory functions.   
Identifying mutations that affect the expression of genes is a crucial task considering that 
these variants remain mostly unknown.  However, variants that affect regulation of genes are 
extremely difficult to characterise since cis-acting regulatory variants can occur in many 
different locations ranging from introns and promoters to control elements that are far away 
(Bray, 2008).  SNPs located in introns can alter transcription, splicing or mRNA stability.  
Transcription can also be affected by SNPs occurring in promoters, while variants in the 
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3’UTR can significantly impact translation.  In each of these cases it is clear that variants in 
regulatory regions will ultimately affect the protein products (Harrison & Weinberger, 2005; 
Perkins et al., 2005).  One example of a regulatory polymorphism, specifically in the African 
population, is a SNP that occurs in the promoter region of the tumour necrosis factor α (TNF-
α) gene.  This results in a new transcription factor binding site (TFBS) for octamer-binding 
transcription factor 1 (Oct-1), which subsequently up-regulates the expression of TNF-α and 
causes an increased risk for cerebral malaria (Prokunina & Alarcón-Riquelme, 2004).  This 
illustrates the importance of considering the roles of affected TFBS for complex disorders.  
Finally, in 2007 Dina et al. indicated that variations within the intronic regions of the fat mass 
and obesity associated (FTO) gene contributes to obesity.  However, direct connections 
between these variants and expression of the FTO gene were difficult to establish.  Recently, 
Smemo et al. (2014) identified iroquois homeobox 3 (IRX3) as a functional distal target of 
FTO.  It was shown that the FTO intronic region contains a number of cis-regulatory 
elements which mediate functional interactions of IRX3.  This finding highlighted the 
significance of non-coding variants as well as the importance of long-range interactions 
between genomic regions. 
It has been suggested that the inconsistent findings of linkage studies might be attributed to 
non-coding RNA (ncRNA) regulation of schizophrenia susceptibility genes (Perkins et al., 
2005).  Variants that occur in the regulatory regions could cause a disruption in gene 
regulation, resulting in altered transcription or translation of genes.  Additionally, ncRNA 
regulation of gene expression is possibly a key process during brain development, which 
would also support the idea of schizophrenia as a neurodevelopmental disorder (Perkins et 
al., 2005).  In addition to this, the possible implications of regulatory variants in 
schizophrenia susceptibility is supported by the increasing number of studies that have 
identified variants associated with schizophrenia within regulatory regions (Palmatier et al., 
2004; Stephens et al., 2009; Zhao et al., 2007).  A prime example of regulatory 
polymorphisms conferring risk of schizophrenia can be found in the case of glutamic acid 
decarboxylase 67 (GAD67) – an enzyme involved in GABA synthesis.  It has been 
demonstrated that increased hypermethylation of the promoter in GAD1, the gene that codes 
for GAD67, may cause a decreased expression of the enzyme, while a SNP in the 5’ region of 
GAD1 may be involved in the onset of schizophrenia during childhood (Costa et al., 2003; 
Addington et al., 2005; Dong et al., 2005).  Lee et al. (2012) suggest that variants conferring 
increased risk for schizophrenia are located across the entire genome and that the architecture 
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of this disorder is polygenic.  In fact, it is estimated that more than 80% of variants are 
located in non-coding regions, which emphasizes the importance of examining these regions 
(Manolio et al., 2009).  However, large research consortia have mainly focussed on the 
coding regions and candidate genes closest to these variants, leaving the remaining 99% of 
the genome unexplored. 
An evaluation of the distribution of SNPs with an effect on gene expression in the human 
genome indicated that 30-60% of SNPs are located in promoter regions and are usually 
located 100bp from the transcription start site (Maston et al., 2006).  This indicates that 
regulatory elements such as promoters might be a “hot spot” for mutations that contribute to 
human diseases.  Furthermore, Maurano et al. (2012) determined that most of the variation 
identified by GWAS occurs in regulatory regions that are marked by DNase hypersensitive 
sites.  This is of particular importance when studying a disorder such as schizophrenia with 
potential disruptions during early development, since 88% of DNase hypersensitive sites are 
active during foetal development.  Furthermore, considering the importance of cis-regulatory 
sequences to mediate transcription factor (trans-regulatory sequences) binding and 
transcription for precise and correct gene regulation during development and function, non-
coding regions have become an attractive research area to understand disease susceptibility 
(Cowie et al., 2013).  One feature of cis-regulatory sequences that is of particular interest to 
the study of diseases is the fact that these sequences can control gene expression in a spatial 
and/or temporal manner.  Therefore, in the event of a variant occurring in such a regulatory 
sequence, the effect will be restricted to a specific tissue or stage of development (Cowie et 
al., 2013).  Finally, regulatory variants could also affect epigenetic DNA and chromatin 
marks, which could provide more clues to understanding the interaction between genetic and 
environmental factors in schizophrenia risk (Sadee et al, 2014). 
The establishment of the ENCODE database (Rosenbloom et al., 2012) has enabled further 
investigation of the human genome.  In 2012, the ENCODE data were published in a series of 
30 research articles in three journals, namely Nature (Volume 489, Issue 7414), Genome 
Research (Volume 22, Issue 9), and Genome Biology (Volume 13, Issue 9).  According to the 
findings of the consortium, 80.4% of the human genome, including over 70 000 promoter 
regions and almost 400 000 enhancer regions is involved in some kind of biological process 
and by their definition, qualifies as a “functional element” (The ENCODE Project 
Consortium, 2012).  This was a milestone event in the understanding of the human genome 
and has caused much anticipation about the potential for improving the understanding of 
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human diseases.  Even though the large amount of ENCODE data has endless possibilities for 
the study of human disease, the highlight of this data is two-fold in that (1) it is possible to 
map many elements in one cell type or (2) one element in many cell types.  The former is 
possible by mapping transcription factors and modified histones across chromatin in a 
specific cell type, while the latter is done by applying DNase-Seq or RNase-Seq to detect 
elements across many different cell types (Dunham, 2013). 
One of the 30 ENCODE series research articles, published by Schaub et al. (2012), 
demonstrated the potential of the ENCODE data by using it to identify functional SNPs in 
regulatory regions and linking these variants to a number of phenotypes.  This study also 
demonstrated that the functional SNP is often one that occurs in LD with the associated SNP 
reported by a GWAS, instead of the reported SNP itself and in many instances the functional 
SNPs were located as far as 170 kb from the lead SNP.  One important example from this 
study was demonstrated with the functional SNP rs1333047 which occurs in a region 
previously associated with coronary artery disease.  While there was no supporting evidence 
for the functional role of the initial reported lead SNP, rs1333049, rs1333047 (which is in 
strong LD with rs1333049) overlapped DNase hypersensitivity and ChIP-seq peaks for 
Signal Transducer And Activator Of Transcription 1 and 3 (STAT1 and STAT3).  
Furthermore, strong LD between these SNPs was only observed in European populations in 
which the lead SNP was initially associated with coronary artery disease, but not in African 
populations, for which the associations with the lead SNPs could not be replicated (Schaub et 
al., 2012).  This has important implications for the interpretation of GWAS results in general 
and highlighted the fact that due to differences in LD patterns between populations, a SNP 
might be associated with a specific phenotype in one population but not another (Schaub et 
al., 2012) 
Another landmark project has been that of the FANTOM consortium - the largest consortium 
to focus on human gene expression.  Early in 2014, the 5
th
 edition of this consortium 
(FANTOM5) published a broad atlas of gene expression in human primary cells, tissues and 
cell lines.  Researchers used Cap Analysis of Gene Expression (CAGE), a technology used to 
identify active genes, in order to monitor the activity of enhancers and promoters in various 
cells.  A staggering 44 000 enhancers and 180 000 promoters were identified and provides the 
most complete overview to date of networks that regulate transcription in specific cell types 
(Forrest et al., 2014).  
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Despite the progress that is being made regarding the non-coding regions of the genome and 
how they could affect gene expression, very little is still known about the various TFBS, the 
factors that bind to these sites and the genes that are regulated by these regions.   
 
2.5 DATA MINING AND BIOINFORMATICS 
Due to the increase in GWAS over the past few years, the development of many databases 
that contain all of the findings and information of these studies have been developed.  An 
example of such a database is HuGE Navigator, a database of human genetic epidemiology 
that is continuously updated and contains records of GWAS among other types of studies (Yu 
et al., 2008).  The availability of such databases provides a more thorough and time-efficient 
way of collecting data from various different studies, which is particularly useful when 
looking at many large studies. 
The findings of both the ENCODE (http://genome.ucsc.edu/ENCODE/) and FANTOM 
(http://fantom.gsc.riken.jp/5/) projects have been made publically available and provides 
researchers with a multitude of options to consider as well as an abundance of data with 
which to work.  In addition to the data that is available, many platforms have recently been 
developed that integrate the findings of these studies with data from other independent 
studies to facilitate data analyses.  One such an example is Haploreg, which was developed 
subsequent to the findings of the ENCODE consortium (Ward & Kellis, 2012).  This tool not 
only provides an attractive way to access the ENCODE data, but combines the findings of 
ENCODE with population based data from projects such as HapMap and 1000 Genomes.  By 
using this approach, a SNP can effectively be analysed for regulatory potential in specific 
populations.  Another tool, GWAS3D, has combined the findings of GWAS with the 
ENCODE data to analyse an entire regulatory region and indicate whether the SNP of interest 
in that region was identified by previous GWAS or is in fact a SNP in LD with the SNP 
identified in the GWAS (Li et al., 2013). 
In addition to the integrative platforms for the analysis of the ENCODE and FANTOM5 data, 
the same approach has also been used to facilitate the analysis of data from other large 
projects such as HapMap (The International HapMap Consortium, 2003) and 1000 Genomes 
(The 1000 Genomes Project Consortium, 2010).  For example, the SNP Annotation and 
Proxy Search (SNAP) Tool provides researchers with a convenient way of working with 
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large sets of SNPs (Johnson et al., 2008).  Instead of evaluating one SNP at a time, it is 
possible to evaluate an entire list of SNPs in order to identify all SNPs that are in LD with 
those SNPs in specific populations.  
These are only a few of the examples of the multitude of tools that are available for data 
mining and analysis.  If used correctly, these tools seem to provide researchers with endless 
possibilities and provide novel strategies to elucidate the underlying genetic mechanisms of 
many complex disorders. 
 
2.6 SCHIZOPHRENIA IN THE SOUTH AFRICAN POPULATION 
A brief overview of 12 schizophrenia GWAS revealed that nine studies focussed on 
individuals of Caucasian descent (Purcell et al., 2009; Stefansson et al., 2009; Ripke et al., 
2011; Steinberg et al., 2011; Bergen et al., 2012; Betcheva et al., 2012; Rietschel et al., 2012; 
Strange et al., 2012; Lencz et al., 2013), two included a Han-Chinese population (Shi et al., 
2011; Yue et al., 2011) and only one study included African American individuals (combined 
with Caucasian individuals) (Shi et al., 2009).  Based on these numbers, it is clear that 
African patients have been under-represented in GWAS, despite the high levels of genetic 
variation in African groups (Schuster et al., 2010) and the fact that schizophrenia accounts for 
approximately 10% of the health burden in sub-Saharan Africa (Lopez et al., 2006).  
Furthermore, it is estimated that of the ~8% of GWAS to include African individuals, only a 
small fraction have focussed on specific populations in Africa (Drögemöller et al., 2011).  
Although an estimated 90% of individuals with the disorder are from developing countries 
(Clark et al., 2011; World Health Organisation, 2013), research in developing countries tends 
to focus more on current epidemics such as HIV, tuberculosis or malaria (Drögemöller et al., 
2011).  Finally, results of studies such as the abovementioned GWAS cannot necessarily be 
extrapolated to African genomes, which further reduces the number of potentially significant 
findings for Sub-Saharan African individuals suffering from schizophrenia. 
To date, the phenotype of schizophrenia among South African Xhosa patients has been well 
studied (Koen et al., 2006; Niehaus et al., 2005, 2008).  Even though little is known about 
what might cause schizophrenia in Xhosa individuals, it is thought that unique cultural factors 
could contribute to onset of the disorder, specifically in young males (Le Roux et al., 2007).  
It has been shown that initiation rites of males that form a pivotal part of Xhosa culture could 
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 2  LITERATURE REVIEW  
23 
 
act as a trigger for the onset of schizophrenia or relapse of a psychotic episode (Le Roux et 
al., 2007).  Additionally, it is likely that cultural factors could also have an impact on how 
psychiatric disorders are perceived within African populations (Yen & Wilbraham, 2003).  
Moreover, stigma associated with mental disorders not only places an unnecessary burden on 
individuals suffering from schizophrenia, but also hinders treatment.   
Only a few studies have researched the genetic basis of schizophrenia in South African 
individuals and such studies have mostly focussed on the Afrikaner population (Hall et al., 
2002; Abecasis et al., 2004; Wiehahn et al., 2004; Hsu et al., 2007; Savitz et al, 2007; Roos 
et al., 2009; Xu et al., 2009; Rodriguez-Murillo et al., 2014).  Nonetheless, it is known that 
Afrikaners are genetically more similar to Europeans than Xhosa or other Sub-Saharan 
individuals and although the phenotype might at first glance appear to be similar between 
patients, studies have shown that there are indeed clinical differences between Xhosa and 
Afrikaner patients (Niehaus et al., 2005).  Therefore it is crucial to include other South 
African populations, more representative of the majority of the nation, in psychiatric genetics 
research.  
Genetic studies conducted in the Xhosa population regarding schizophrenia risk, have 
investigated variants in the potassium intermediate/small conductance calcium-activated 
channel, subfamily N, member 3 gene (KCNN3) and protein phosphatase 2, regulatory 
subunit B, beta (PPP2R2B), both known to have a role in the central nervous system and 
superoxide dismutase 2, mitochondrial (MnSOD) (Laurent et al., 2003; Hitzeroth et al., 
2007).  However, association analyses failed to link any of these genes to schizophrenia risk 
in the Xhosa population.  A series of studies conducted by Riley et al. (1996a; 1996b; 2000; 
2002) investigated regions on chromosomes 6, 9, 12, 13, 15, 17 and 22 in the South African 
Bantu-speaking population, which includes Xhosa individuals.  The most significant findings 
were the association of polymorphisms in the coding regions of the alpha-7 acetylcholine 
receptor gene (CHRNA7) as well as the subunits that code for NMDA receptors, glutamate 
receptor ionotropic NMDA 1, 2B and 2C (GRIN1, GRIN2B, GRIN2C).  Nonetheless, Riley et 
al. (1996a; 1996b) was unable to identify a significant association between various 
chromosome 6p and chromosome 22 markers and schizophrenia in the Bantu-speaking 
individuals.  These regions have consistently been associated in genetic studies of 
schizophrenia that included individuals of European descent and emphasizes the fact that 
findings from one population are not necessarily applicable to another population.  However, 
this is not always the case.  In 2012, Wright et al., identified associations between COMT 
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genetic variants and schizophrenia susceptibility in a Xhosa cohort of 238 schizophrenia 
patients and 240 healthy individuals.  This supported previous associations of COMT with 
schizophrenia in other populations (Shifman et al., 2002; Chen et al., 2004) 
African populations are particularly important in the study of complex diseases due to greater 
levels of genetic diversity and genetic adaptations as a result of environmental effects 
amongst others.  Furthermore, these groups have extensive population substructure and less 
linkage disequilibrium (LD) between loci in comparison with other populations (Campbell & 
Tishkoff, 2008).  Of the approximately 52 million individuals that constitute the South 
African population (Statistics South Africa, 2013), approximately 9 million individuals 
belong to the Xhosa population, which makes it the second largest ethnic group in the country 
(Department of Government Communication and Information System, 2013).  The 
importance of including Xhosa individuals in genetic studies is demonstrated by the fact that 
they are an ethnically homogenous group, which means that confounding factors and, in the 
case of schizophrenia, phenotypic heterogeneity, is limited (Niehaus et al., 2005).  
Furthermore, due to the fact that African populations are the oldest, valuable information can 
be obtained through genetic studies that include groups such as the Xhosa population. 
Given the current statistics for South African individuals with psychiatric disorders, the state 
of mental health care and the lack of understanding of these disorders, it is clear that this area 
requires a great deal of research.  Early diagnosis is vital for improved treatment outcomes; 
therefore identifying the genetic causes of schizophrenia can aid in understanding the 
disorder and thereby facilitate accurate and early diagnoses in the future.  Additionally, 
understanding the genetic architecture of schizophrenia may allow for treatment to be 
optimised which would improve treatment response and limit the current ADRs associated 
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2.7 AIMS & OBJECTIVES 
In an effort to contribute to the elucidation of the underlying genetic components of 
schizophrenia, this study used a novel approach based on data-mining and the utilization of 
bioinformatics tools to study the variants involved in schizophrenia susceptibility.  Non-
coding regions were examined instead of only investigating genes most closely linked to 
significant variants.  The strength of this study lied in the abundant data available for analyses 
as well as the unique, clinically well characterised, Xhosa cohort investigated.  It was hoped 
that by broadening the genetic focus to include non-coding regions, a more comprehensive 
overview of the genetic architecture of schizophrenia would be determined. 
The aim of this study was to identify regulatory regions which could potentially be involved 
in schizophrenia susceptibility and to determine which genes are regulated by these regions.   
The main objectives of this study included the following: 
 Mine existing databases containing GWAS data (e.g. HuGENavigator) as well as the 
literature, to identify variants that have significantly (P ≤ 5x10
-8
) been associated with 
schizophrenia susceptibility. 
 Identify variants that are in linkage disequilibrium (LD) with the abovementioned 
polymorphisms, using databases containing known variation such as HapMap and the 
1000 Genomes Project. 
 Determine whether any of the identified variants occur within regulatory regions with 
the use of ENCODE or other relevant data. 
 Characterise any variation in regulatory regions with the use of predictive programs to 
determine the effect that the variants have on the function of the regulatory regions. 
 Identify genes that are regulated by these regulatory regions using ENCODE data. 
 Perform pathway and network analysis based on the predicted affected genes. 
 Genotype the most significant variants in the South African Xhosa cohort. 
 Perform statistical analyses to determine a possible association between significant 
variants and schizophrenia susceptibility within the Xhosa population.  
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IDENTIFICATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN 




Schizophrenia is a debilitating mental disorder, which remains poorly understood.  Despite 
the increase in GWAS focussing on this disorder over the past few years, most significant 
associations have been for variants in non-coding regions.  This study aimed to analyse 
variants in these regions that could be associated with schizophrenia susceptibility.  Variants 
associated with the disorder by GWAS as well as all variants occurring in LD with these were 
identified.  Using a range of freely available data and webtools (ENCODE, FANTOM5, 
RegulomeDB, rSNPBase, GWAS3D), variants were analysed for regulatory potential as well 
as potential effects on motifs, protein binding and gene expression.  Finally, pathway and 
network analysis (using DAVID and GeneMANIA) were performed.  This study provided 
evidence for regulatory variants in regions previously associated with schizophrenia risk, but 
also identified novel variants with strong regulatory evidence that could be involved in 
schizophrenia susceptibility.  The most significant of these was rs200981, a variant with 
regulatory effects on genes located in the major histocompatibility (MHC) region as well as a 
number of histone protein genes in the extended MHC region.  This provides support for the 
hypothesis of an immune component conferring an increased risk for schizophrenia.  
Additionally, this variant was shown to affect processes crucial to DNA, nucleosome and 
chromatin packaging.  Furthermore, many of the variants identified to have regulatory 
potential have been implicated in neurodevelopment, which in addition provides supporting 
evidence for this hypothesis.  It is suggested that further research should focus on two areas 
of interest: (i) interactions between the genetic architecture of immune responses and 
dysregulation in neurodevelopment and (ii) aberrant DNA packaging involved in 
schizophrenia susceptibility. 
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Over the past few years there has been a significant increase in the number of GWAS to 
identify genetic variants that are associated with a wide variety of disease and traits.  
However, the majority of variants that have been associated with any specific disorder seem 
to occur in non-coding regions.  While most GWAS initially focussed on the closest genes to 
variants in these regions, the release of the ENCODE data has made it possibly to focus more 
specifically on the genes that are actually affected by variants in non-coding regions, whether 
it is due to proximal or distal interactions. 
Since the release of the ENCODE data there has been a surge of disease studies focussing on 
the link between variants in non-coding regions and disease phenotype.  It has been shown, 
for example, that variants which were associated with a disorder in a GWAS, but with no 
supporting functional evidence, could occur in strong LD with a SNP that overlaps with 
DNase hypersensitive sites or ChIP-seq peaks.  A study published by Schaub et al. (2012), 
demonstrated the potential of the ENCODE data by using it to identify functional SNPs in 
regulatory regions and linking these variants to a number of phenotypes.  This study also 
demonstrated that the functional SNP is often one that occurs in LD with the associated SNP 
reported by a GWAS, instead of the reported SNP itself.  These findings, combined with the 
traditional identification of functional variants in protein-coding regions, could provide better 
insights into the molecular mechanisms by which certain genes are affected by 
polymorphisms. 
Due to the increase in next generation sequencing studies, there has also been an increase in 
the amount of data generated.  As the analysis of large datasets is rather time-consuming, this 
has inevitably caused somewhat of a bottleneck in research outputs.  In an effort to make data 
mining and handling more efficient, many tools currently exist that can be applied to any 
study of human diseases and disorders.  GWAS databases are usually the first tools to be 
accessed when identifying variants associated with a specific disorder.  While many 
databases exist, HuGE Navigator and the NHGRI Catalog of Published GWAS are two of the 
most popular, convenient and user-friendly databases which are regularly updated.  As of 1 
July 2014, the NHGRI Catalog contains information from 1926 studies and 13403 SNPs.  
Additional databases useful for the analysis of human variation include HapMap and 1000 
Genomes.  However, tools that combine the information of both these databases, such as the 
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SNAP tool, provide an even more convenient alternative when working with large sets of 
data.   
Traditional analysis of variants associated with human disease have relied on applications 
such as Sorting Intolerant from Tolerant (SIFT) and Polymorphism Phenotyping (PolyPhen) 
which annotate variants in protein-coding regions.  However useful this may be, the results of 
these applications might be better understood if combined with tools that are capable of 
annotating variants in non-coding regions as well.  Such bioinformatic tools include 
RegulomeDB, Haploreg, GWAS3D and rSNPBase.  These applications act as integrative 
platforms which combine information from the ENCODE studies with those of HapMap and 
1000 Genomes in order to provide a more comprehensive overview of the variants involved 
in human disorders.  Importantly, due to the plethora of tools available, there is currently no 
set protocol for the analysis of large sets of SNPs in non-coding regions.  It is likely that as 
current tools are improved, the most effective methods for analysis will become more 
apparent. 
This study will use the abovementioned databases and bioinformatic applications to identify 
variants specifically in regulatory regions which are associated with schizophrenia 
susceptibility.  This disorder is still poorly understood and is difficult to diagnose.  While the 
aetiology of schizophrenia eludes researchers, it is expected that a multitude of variants will 
be involved in the genetic architecture.  This disorder serves as a perfect case study to test the 
hypothesis of linking variants in coding regions to variants in non-coding regions, due to the 
plethora of associated variants in the latter.  Furthermore, an intricate network of linked 
variants might explain the complexity of the disorder as well as the general inability to 
replicate findings between studies.   
This study provides a relatively simple method for identifying and analysing schizophrenia 
associated variants that occur in regulatory regions.  Furthermore, this method could in theory 
be applied to the study of any disorder or trait. 
 
3.3 MATERIALS & METHODS 
3.3.1 Strategy 
An overview of the strategy used for this study is summarized in Fig. 3.1. 
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Figure 3.1.  Flowchart of the strategy used to identify and analyse variants in non-coding 
regions. For the identification of SNPs in regulatory regions, a RegulomeDB score above 3b 
indicates that a variant is likely to affect binding. 
 
3.3.2 Data Sets 
Publically available data was used for this study.  GWAS data from the PGC (Ripke et al., 
2011), ISC (Purcell et al., 2009) and MGS (Shi et al., 2009) as well as eight additional 
SNPs from GWAS  
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studies were used (Accessed February 2013, with the exception of one GWAS by Lencz et 
al., 2013 which was accessed August 2013).  Furthermore, data from the 1000 Genomes and 
HapMap consortia were also accessed for each of the populations corresponding to the 
populations used in the respective GWAS. 
 
3.3.3 Significant SNPs from GWAS 
All significant SNPs from previous schizophrenia GWAS were identified using HuGE 
Navigator (Yu, et al. 2008; Accessed February 2013), the NHGRI Catalog of Published 
GWAS (Hindorff et al., 2009; Accessed February 2013) as well as a literature search, using 
terms such as “schizophrenia susceptibility”, “schizophrenia GWAS” and “schizophrenia 
susceptibility GWAS”.  Due to the multiple tests performed for a GWAS, there is a greater 
likelihood of false positive associations.  Therefore, in order to determine appropriate 
genome-wide significance, a stringent threshold value is crucial and has been estimated to be 
approximately P ≤ 5x10
-8 
(Risch & Merikangas, 1996).  Only variants surpassing this 
threshold were selected. 
 
3.3.4 SNPs in linkage disequilibrium 
To identify all SNPs that occur in LD with the significant SNPs obtained from GWAS, the 
SNAP search tool was used (Johnson et al., 2008; Accessed April 2013).  This web-based 
tool utilizes data from both the 1000 Genomes Project (The 1000 Genomes Project 
Consortium, 2010) as well as HapMap (The International HapMap Consortium, 2003).  It is 
extremely important to evaluate SNPs that are in LD, because often the reported significant 
SNP is actually in LD with a functional SNP.  These databases contain extensive information 
regarding human variation, for example 1000 Genomes (The 1000 Genomes Project 
Consortium, 2010) contains information for approximately 38 million SNPs.  Taking into 
consideration that the significant SNPs from previous GWAS were significant in different 
populations, analyses of LD in various populations had to be done.  The list of significant 
SNPs was divided into three groups according to the populations in which the variants were 
identified, namely European, Asian and African American.  These groups of SNPs were each 
uploaded to SNAP separately to search for SNPs that occur in LD with the significant SNPs 
identified by GWAS, in the Northern Europeans from Utah (CEU), Yoruba in Ibadan, 
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 3  BIOINFORMATIC ANALYSES  
32 
 
Nigeria (YRI) and finally, Han Chinese in Beijing, China and Japanese in Tokyo, Japan 
(CHB+JPT) populations.  For each set of SNPs and in each population, 1000 Genomes, 
HapMap release 21, release 22 and 3 was searched.  Threshold values included an r
2
-value of 
0.8, to select for SNPs in strong LD, and distance limit of 500 kb.  Even though SNPs that are 
separated by larger distances could be in LD, this distance limit is the largest possible limit 
when using SNAP.  This is due to the fact that the HapMap consortium only did pairwise LD 
calculations for SNPs within 500 kb of one another and that LD signal tends to decrease 
significantly beyond 500 kb (Johnson et al., 2008).  Finally, the list of resulting SNPs was 
filtered for SNPs in LD with a D’ value of 1. 
 
3.3.5 SNP annotation 
SeattleSeq Annotation 137 (National Heart, Lung, and Blood Institute, 2013; Accessed May 
2013) was used for functional annotation of the significant SNPs from previous GWAS as 
well as all SNPs occurring in LD with these SNPs.  As with all the other programs used for 
analysis, the annotation based on the human genome reference sequence GRCh37 was 
selected.  The list of SNPs to be annotated was uploaded in a custom format, which included 
chromosome, location, reference allele and first allele.  The resulting file contained 
information from various programs related to annotation.  The results of the Genome 
Variation Server (GVS) database were used to create an overview of the SNPs involved.  
Furthermore, results of PolyPhen (Adzhubei et al., 2010) were used to identify functional 
variants.  Variants predicted to be “probably damaging” or “possibly damaging” were 
selected for further analyses.   
 
3.3.6 SNPs in regulatory regions 
Based on the results of SNP annotation that indicated most SNPs associated with 
schizophrenia susceptibility are not located in any known genes, it was necessary to 
determine which of the SNPs identified in GWAS and those in LD occur in regulatory 
regions.  RegulomeDB (http://regulome.stanford.edu/; Accessed May 2013) is a tool which 
assists in the identification and interpretation of regulatory polymorphisms by using 
ENCODE datasets amongst others, and providing scores to identify potentially functional 
variants.  Prediction methods that are used by RegulomeDB are based on the potential effects 
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of variants on binding motifs and DNase footprinting that indicates which proteins will bind 
to a specific site.  The data that is used include chromatin state, expression quantitative trait 
loci (eQTL) and CHIP-seq information as well as manually curated regulatory regions.  
Finally, scores are based on available eQTL, TF binding, TF motif, DNase footprint and 
DNase peak information.  Scores between 1a and 3b indicate that a variant is likely to affect 
binding and were therefore included for further analyses.  Importantly, RegulomeDB was 
also used due to the scoring system (specific for regulatory polymorphisms) that is 
automatically implemented in this application (Table 3.1), which served as a means of 
prioritizing significant variants. 
Table 3.1.  Scoring system used by RegulomeDB (Boyle et al., 2012). 
SCORE DATA AVAILABLE TO SUPPORT SCORE 
1a 
eQTL + TF binding + matched TF motif + matched DNase  
Footprint + DNase peak 
1b 
eQTL + TF binding + any motif + DNase Footprint + DNase  
peak 
1c eQTL + TF binding + matched TF motif + DNase peak 
1d eQTL + TF binding + any motif + DNase peak 
1e eQTL + TF binding + matched TF motif 
1f eQTL + TF binding / DNase peak 
  
2a 
TF binding + matched TF motif + matched DNase Footprint  
+ DNase peak 
2b TF binding + any motif + DNase Footprint + DNase peak 
2c TF binding + matched TF motif + DNase peak 
  
3a TF binding + any motif + DNase peak 
3b TF binding + matched TF motif 
  
4 TF binding + DNase peak 
5 TF binding or DNase peak 
6 other 
 
3.3.7 Affected regulatory elements and related genes 
Apart from determining the potential effects of variants with RegulomeDB, tools such as 
GWAS3D (Li et al., 2013; http://jjwanglab.org/gwas3d; Accessed February 2014) and 
rSNPBase (Guo et al., 2013; http://rsnp.psych.ac.cn/; Accessed May 2014) were also used to 
Likely to affect 
binding and linked 
to expression of a 
gene target 
Likely to affect 
binding 
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identify proximal and distal interactions for all variants with a RegulomeDB score between 
1a and 3b.  GWAS3D is an integrative web server that uses information based on genome-
wide associations, chromatin states and chromosome interactions to analyse human 
regulatory variants (Li et al., 2013).  rSNPBase is a database of curated regulatory SNPs 
(rSNPs) which have been annotated with reference to experimentally validated regulatory 
elements (Guo et al., 2013).  While GWAS3D is effective in identifying proximal and long-
range interactions between a regulatory variant and a genome region, rSNPBase is somewhat 
more effective and precise in identifying which type of regulation is being affected (proximal 
and distal transcriptional regulation and post-transcriptional regulation) and can identify the 
potentially regulated genes.  Analysis with GWAS3D was done by uploading the list of SNPs 
in single SNP ID (dbSNP) format.  The option for “without GWAS association statistics” was 
selected, since this had been done previously.  The list of SNPs were analysed for regulatory 
effects in the various relevant populations, using the Hapmap I+II+III or 1000 Genomes Pilot 
1 SNP data set.  All other default values were used.  For analysis with rSNPBase, the “list 
search” option was used, after which the list of regulatory SNP IDs were uploaded.   
Additionally, the Transcription Factor Affinity Prediction (TRAP) tool (Thomas-Chollier et 
al., 2011), which is a unix-based application, was also used to determine which SNPs affect 
TFBS.  More specifically, sTRAP was used which investigates how potential TFBS are 
affected by differences in sequences.  The advantages of sTRAP include the fact that the 
program does not rely on a threshold value, but rather that all positions in a given sequence 
are used to determine the affinity for a transcription factor in the presence of a SNP and that 
the program relies on collections provided by the JASPAR (Bryne et al., 2008) and 
TRANSFAC® (Matys et al., 2006) databases.  While a web-based version of this tool is 
available, the R-package of sTRAP is more effective when analysing large amounts of 
variants at once.  The program requires two files: firstly a FASTA file with the SNP of 
interest as well as a select number of bp before and after the SNP, and secondly a PAIRS file 
that simply defines which sequences containing the “wild type” or “mutated” alleles go 
together.  For the first file, all of the SNPs from previous GWAS as well as those in LD were 
analysed.  The list of SNPs had to be in a Browser Extensible Data (BED) file.  Thereafter, 
BED files representing the genomic region 15 bp before and after each SNP were also 
generated (in separate files).  Subsequently, FASTA files were generated for each SNP as 
well as the defined regions before and after each SNP.  Finally, these FASTA files had to be 
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combined; therefore the script “weave_fasta_for_sTRAP.pl” was written (Appendix 2).  
Using this file, along with the PAIRS file, sTRAP could analyse each SNP. 
Importantly, in order to determine whether any TFBS were enriched for schizophrenia 
specifically, a set of controls were also analysed with sTRAP.  Four additional, random 
disorders/traits were selected including Bipolar Disorder, Hypertension, Diabetes and Height.  
For each of these disorders, the most significant SNPs from GWAS as well as the SNPs in 
LD were identified and then analysed with sTRAP.  Additionally, SNPs surrounding the 
previously analysed SNPs associated with schizophrenia susceptibility were also analysed 
with sTRAP.  For this, the “slop” function in BedTools was used to identify all SNPs in the 
50bp before and after each of the SNPs associated with schizophrenia susceptibility before 
the SNPs could be analysed with sTRAP.  Once the final results were obtained, the affected 
motif identifiers had to be searched on the Jaspar Core Database (http://jaspar.genereg.net/; 
Accessed September & October 2013).  Only motifs related to H. sapiens were selected. 
Finally, the expression of the most frequently affected genes was assessed using FANTOM 
data.  While there are many tools that incorporate FANTOM data, the Semantic catalogue of 
Samples, Transcription initiation And Regulators (SSTAR) was used for this study 
(http://fantom.gsc.riken.jp/5/sstar/; Accessed May 2014).  Each gene was searched on the 
database, specifically in H. sapiens (Taxonomy ID: 9606).  After the results were obtained 
for all cell lines, only results for cells related to the human brain were selected.  Six cell lines 
were relevant, namely: (i) Smooth Muscle Cells - Brain Vascular, donor2.CNhs11900.11315-
117D1, (ii) Smooth Muscle Cells - Brain Vascular, donor1.CNhs10863.11234-116D1, (iii) 
Smooth Muscle Cells - Brain Vascular, donor3.CNhs12004.11391-118C5, (iv) brain, adult, 
pool1.CNhs10617.10012-101C3, (v) brain, adult, donor1.CNhs11796.10084-102B3, (vi) 
brain, fetal, pool1.CNhs11797.10085-102B4.  The average expression level, in tags per 
million (TPM), of each affected gene was calculated over the six cell lines. 
 
3.3.8 Pathway Analysis 
Pathway analysis was performed using the Database for Annotation, Visualization and 
Integrated Discovery version 6.7 (DAVID v6.7; http://david.abcc.ncifcrf.gov/; Accessed June 
2014).  The advantage of using DAVID is that the tool relies on novel functional annotation 
algorithms/tools and can easily group large gene sets into functional clusters.  This tool relies 
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on key concepts such as the “DAVID Gene Concept” which uses a graph theory evidence-
based method to identify and group genes or proteins from a variety of public genomic 
resources and the “Term/Gene Co-Occurrence Probability” concept which analyses the co-
occurrence of functions with sets of genes.  This facilitates biological interpretation of 
significant findings.  Therefore, DAVID was used in order to determine which pathways are 
overrepresented by the predicted affected genes.  Functional annotation clustering (using the 
DAVID Functional Annotation Clustering Tool) was performed by uploading a list of genes 
consisting of the genes affected by damaging SNPs (as predicted by Polyphen) as well as the 
genes affected by variants in non-coding regions with a RegulomeDB score of 3b or higher 
(as predicted by RegulomeDB and rSNPBase).  All default checked items were unchecked 
and only the tools related to pathway analysis, namely Biological Biochemical Image 
Database (BBID), BioCarta, Kyoto Encyclopedia of Genes and Genomes (KEGG), Protein 
Analysis Through Evolutionary Relationships (PANTHER) and REACTOME were checked.  
Pathways specific to H. sapiens were selected.  Ideally, only annotation clusters with an 
enrichment score of 1.3 or higher would be considered significant since a score of 1.3 is 
equivalent to non-log scale 0.05, however it is also important that clusters with lower 
enrichment scores should still be considered for further analyses since these clusters might 
contain individual genes of importance (Huang et al., 2009a; 2009b).  Finally, DAVID uses 
the Benjamini-Hochberg method to correct for multiple comparisons. 
 
3.3.9 Network Analysis 
In addition to performing the required pathway analysis of the genes predicted to be involved, 
network analysis was also performed using GeneMANIA (http://www.genemania.org/; 
Accessed June 2014) in order to determine whether any of the predicted pathways fit within a 
specific network.  GeneMANIA is a publically available web-based tool which identifies 
additional genes related to a set of query genes.  This is made possible using co-expression 
data from Gene Expression Omnibus (GEO), genetic and protein interactions data from 
BioGRID and I2D, and finally pathway interaction data from Pathway Commons.  As of June 
2014, GeneMANIA has a database of 2,104 association networks containing 535,774,338 
interactions mapped to 161,629 genes from eight organisms (http://www.genemania.org/, 
June 2014).   
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Furthermore, GeneMANIA uses one of two weighting methods (Warde-Farley et al., 2010).  
The first is used for longer gene sets, during which GeneMANIA learns from the uploaded 
gene set and integrates as few new genes into the predicted network as possible, resulting in a 
more accurate network prediction.  However, in the event of shorter gene lists being used (as 
in this study), the second method is used which is similar to the first weighting method, but 
GeneMANIA will learn from Gene Ontology (GO) biological process annotations instead of 
the actual gene set. 
For network analysis, only genes identified in selected pathways according to DAVID were 
uploaded to GeneMANIA and searched within H. sapiens.  All default parameters were left 
checked.  GeneMANIA also uses Benjamini-Hochberg multiple testing correction and only 
GO terms with a false discovery rate (FDR) of < 0.05 are reported. 
 
3.4 RESULTS 
3.4.1 SNP Annotation 
A total of 64 SNPs passing the threshold for genome-wide significance (p ≤ 5x10
-8
) from 
previous studies that investigated variants associated with schizophrenia susceptibility, were 
identified (Table S1).  Furthermore, 1670 SNP in LD with the SNPs from GWAS were 
identified.  Annotation of the combined total of 1734 SNPs with SeattleSeq-137 is 
summarised in Fig. 3.2. 
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Table 3.2.  Annotation of functional SNPs. 












rs200484 6 27775674 A/G missense LEU,PRO 4/127 benign 0.497 HIST1H2BL 








rs1635 6 28227604 A/C missense THR,ASN 152/403 benign 0.003 NKAPL 




rs33932084 6 28268824 A/G missense ASN,SER 398/810 benign 0.992 PGBD1 
rs2232423 6 28366151 A/G missense MET,THR 11/612 benign 0 ZSCAN12 




rs3132580 6 30920124 A/G missense GLU,LYS 1295/1394 benign 0 DPCR1 
rs1150752 6 32064726 C/T missense THR,ALA 302/4243 benign 0.376 TNXB 




rs1265754 6 32303692 A/T missense ILE,PHE 150/564 unknown 1 C6orf10 
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Only 13 SNPs were predicted to cause missense mutations.  However, of these 13 only six 
were predicted to be probably or possibly damaging by PolyPhen (Table 3.2). 
 
3.4.2 SNPs in regulatory regions 
Annotation of the SNPs in non-coding regions with RegulomeDB predicted 149 SNPs to 
have some type of regulatory potential.  While Table 3.3 only contains the ten most 
significant SNPs that are most likely to affect binding and are linked to the expression of a 
gene, the remaining SNPs with a score of 1a-3b are summarized in Table S2.   



































rs13211507 28257376 3.80E-11 27775696 481680 















rs2021722 30174130 2.18E-12 30231767 -57637 
rs886424 30782001 6 4.54E-08 
rs886424 30782001 C/T 1b 0 








rs1488935 38133792 5.06E-09 38226276 -92484 
rs2905424 19473444 19 3.44E-09 
rs4808967 19640523 T/C 1b -167079 
rs4808203 19568658 T/C 1b -95214 
a
Score was predicted by RegulomeDB. 
b
Distance of regulatory variant from lead SNP. 
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3.4.3 Affected regulatory elements 
The resulting affected regulatory elements by the top 10 variants in regulatory regions as 
predicted by RegulomeDB, rSNPBase and sTRAP are summarized in Table 3.6. 
Furthermore, the top 10 genes predicted to be affected by all of the identified SNPs in 
regulatory regions (Table S2) by RegulomeDB and rSNPBase, as well as the corresponding 
expression levels in specific cell lines are summarized in Tables 3.4 and 3.5 respectively. 







HLA-A 6 26 162.48 
USMG5 10 18 223.82 
BTN3A2 6 12 2.46 
HLA-H 6 8 0.24 
HLA-DQA1 6 8 6.73 
KIAA0892 19 7 79.15 
HLA-DRB1 6 7 1.38 
EDG4 19 7 2.07 
ATP13A1 19 7 28.59 
HLA-G 6 6 0.33 







CNNM2 10 24 7.50 
HIST1H2AH 6 23 208.33 
ZSCAN31 6 21 3.87 
MIR3143 6 21 NA 
HIST1H2BK 6 20 39.41 
HIST1H2AG 6 20 208.33 
HIST1H2BJ 6 17 39.68 
GATAD2A 19 17 13.18 
HIST1H4I 6 15 594.76 
NT5C2 10 13 22.50 
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MIR3143, ZNF391, ZSCAN31, 
HIST1H2AD, HIST1H3D, 
HIST1H2BF, HIST1H4E, 
PRSS16, ANKRD17, HIST1H4H, 
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HIST1H2BF, PRSS16, TOB2P1, 






















ZSCAN31, OR2B6, SCAND3, 
HIST1H2BG, HIST1H2AE, 
HIST1H4I, LPCAT1, HIST1H1E, 
HIST1H2BD, HIST1H2APS4, 
HIST1H2BI, HSP90AB1, RNU5E-
























Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za



































YJEFN3, TSSK6, NDUFA13, 
GMIP, ATP13A1 















 Variant and effect predicted by RegulomeDB. 
b
 Associated genes were predicted by rSNPBase. 
c
 Motifs were predicted by RegulomeDB, however motifs that are underlined were predicted to be affected by sTRAP. 
d
 Novel variants linked to schizophrenia are indicated in bold.  
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Finally, circle plots are easily generated by GWAS3D, which depict the intricate interactions 
between various regions of the genome.  Since analysis of the variants between the different 
populations (CEU, CHB+JPT, YRI) showed subtle differences between the numbers of 
affected regulatory elements, the results for the YRI population were used for further analysis 
(Fig. 3.3).   
 
Figure 3.3.  Circle plot depicting the interactions between various SNPs associated with 
schizophrenia susceptibility for the YRI population, across all cell lines.  The cluster of 
interactions between histone protein genes on chromosome 6 is circled in yellow. Stronger 
interactions are indicated with thicker red lines. 
 
Importantly, analysis with sTRAP not only indicated which TFBS were affected by the 
presence of a specific SNP, but also showed similar results between the affected TFBS of 
schizophrenia and the control disorders/traits.   
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3.4.4 Pathway analysis 
Only one cluster was obtained for the set of query genes (Table 3.7); however this cluster had 
a relatively high enrichment score (4.69).   
The terms in the cluster, as identified by the indicated pathway analysis tools in column 1, are 
sorted according to p-value which is calculated using a modified Fisher’s exact test.  The 
count indicates the number of query genes that fit the term.   
Table 3.7.  Pathway analysis of genes affected by significant variants in regulatory regions. 
CLUSTER 1: ENRICHMENT SCORE = 4.69 
Pathway 
Analysis Tool 
Term Count p-value Benjamini 
KEGG Allograft rejection 10 2.79E-09 1.17E-07 
KEGG Graft-versus-host disease 10 6.04E-09 1.69E-07 
KEGG Type I diabetes mellitus 10 1.22E-08 2.57E-07 
KEGG Autoimmune thyroid disease 10 7.44E-08 1.25E-06 
KEGG Antigen processing and presentation 11 5.67E-07 7.94E-06 
KEGG Viral myocarditis 9 1.38E-05 1.66E-04 
KEGG Asthma 6 7.97E-05 8.36E-04 
KEGG Cell adhesion molecules (CAMs) 10 2.18E-04 2.04E-03 
KEGG Intestinal immune network for IgA production 6 9.97E-04 8.35E-03 
REACTOME Signaling in Immune system 13 1.91E-02 2.27E-01 
KEGG Natural killer cell mediated cytotoxicity 4 3.56E-01 9.41E-01 
KEGG Hematopoietic cell lineage 3 3.40E-01 9.53E-01 
 
 
3.4.5 Network analysis 
The results of GeneMANIA were ranked according to the FDR value (or q-value), which is 
the significance value after correction for multiple testing.  According to this value, the most 
significant GO term was “endoplasmic reticulum (ER) to Golgi transport vesicle membrane” 
(Fig. 3.4), with a FDR of 8.38x10
-42
.  However, when focussing on the network terms with 
the most genes that fit into the network, “antigen processing and presentation of exogenous 
peptide antigen” would be considered the most significant term, with 24 genes matching this 
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function (Table S3).  The full network, including query genes and additional genes identified 
to match the pathway of a specific phenotype are depicted in Fig. S1.   
Additionally, when considering each of the genes separately, the gene encoding HLA-DR 
beta 5 (HLA-DRB5) had the highest ranking score (80.32) in terms of association with other 
genes in the query list and the weight of these associations / paths (Fig. S2). 
 
 
Figure 3.4.  Network analysis with GeneMANIA.  Nodes representing genes that fit the most 
significant network “ER to Golgi transport vesicle membrane” are highlighted in red. 
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The goal of this study was to analyse variants within non-coding regions of the genome, 
which could affect gene regulation and potentially contribute to schizophrenia susceptibility.  
Significant SNPs from previous GWAS, as well as the corresponding variants in LD, were 
analysed using a bioinformatics pipeline that was established during this study.  Although 
bioinformatic analyses are largely predictive, many of the datasets used in this study 
comprised experimentally validated data.  Furthermore, the advantage of using bioinformatic 
tools lies in the possibility to analyse large datasets to create a comprehensive overview of 
variants associated with a specific disorder. 
Considering the fact that most variants are located in non-coding regions, the standard 
approach of analysing the effects of non-synonymous mutations on the gene products of 
protein coding genes seems inadequate when studying complex disorders.  Therefore this 
study used a different approach, whereby non-coding variants were analysed.  However, the 
most effective analysis will include non-coding as well as protein coding regions. 
 
3.5.1 Significant variants 
The first significant finding of this study is the fact that 12 of the 13 functional variants, as 
predicted by PolyPhen, occurred on chromosome 6 (Table 3.2).  This was not surprising, 
since this is the most consistently linked region to schizophrenia susceptibility in the human 
genome (Purcell et al., 2009; Shi et al., 2009; Stefansson et al., 2009).  Furthermore, 
functional annotation of the variants predicted to be associated with the disorder highlighted 
the need to analyse non-coding regions of the genome.  This was proved by the fact that only 
13 of the initial 1734 variants (identified by previous GWAS and linkage disequilibrium 
analysis in this study), that were analysed were predicted to cause missense mutations, of 
which a mere six SNPs had “probably damaging” or “possibly damaging” effects (Table 3.2).   
Of the top 10 SNPs in regulatory regions, rs200981 was the most significant, with a 
RegulomeDB score of 1a.  Furthermore, this SNP appeared to affect one nearby gene, 
Hs.158943 (an associated eQTL, but with unknown function) and affected a total of 25 distal 
genes (Table 3.6).  This SNP is located in the MHC region on chromosome 6.  It is important 
to reiterate that this specific region contains the most significant and best replicated GWAS 
findings associated with schizophrenia to date (Purcell et al., 2009; Shi et al., 2009; 
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Stefansson et al., 2009).  Furthermore, this SNP predominantly affected extended MHC 
histone protein genes, which have previously been linked to schizophrenia and are mainly 
involved in the regulation of DNA transcription and repair (Müller & Schwarz, 2010).  This 
highlights the possibility of mutations in fundamental regulatory processes that could 
contribute to schizophrenia vulnerability.   
SNP rs200981 is in LD with two SNPs, rs17693963 and rs13211507, which have previously 
been associated with schizophrenia susceptibility in two separate GWAS in the European 
population (Stefansson et al., 2009; Bergen et al., 2012).  However, as with many GWAS 
findings, there was no functional evidence to support the association of these two SNPs, only 
the regions that it was located in.  In contrast, rs200981 was found to overlap with an E2F 
transcription factor 1 (E2F-1) DNase footprint region as well as a number of ChIP-seq peaks 
(for POLR2A, GATA1, HEY1, E2F1, E2F4, EP300, TBP, NFKB1, GTF2F1, YY1, CDX2, 
TAF1, SPI1, POU2F2, JUND, SIN3A and TAF7), which indicates affected protein binding 
(Table 3.6).  One of the affected proteins of particular interest was E1A binding protein p300 
(EP300) – a protein which is critical for the regulation of cell growth and division.  
Furthermore, this protein also ensures normal development before and after birth (Eckner et 
al., 1994).  Importantly, this gene has previously been linked to schizophrenia in a European 
cohort and more recently in the largest psychiatric GWAS to date, where more than 150 000 
individuals were included (Severinsen, 2006; Ripke et al., 2014).  Additional analysis of 
affected TFBS with sTRAP, indicated that TF affinity was affected at four other sites, namely 
NR2F1, HNF4A, NR1H2::RXRA and NFIC (Table 3.6).  The largest change in TF affinity 
was for NR2F1, with a 23-fold increase for this TF at the related TFBS.  Further analysis 
with rSNPBase, indicated a large number of additional genes that were potentially also 
affected by rs200981 (Table 3.6).  Importantly, the histone cluster 1, H2b, Pseudogene 2 
(HIST1H2BPS2) was affected through proximal transcriptional regulation, the histone cluster 
1H2al gene (HIST1H2AL) by RNA binding protein mediated regulation and the rest of the 
genes by distal transcriptional regulation.  Despite the surplus of information obtained for this 
regulatory SNP, the exact mechanism by which it could affect the predicted regulatory 
elements and genes remains unclear.  Considering that E2F-1 belongs to the E2F family of 
transcription factors, which play an important role in the 1
st
 gap phase / synthesis gap phase 
(G1/S) transition of cell cycle control and the action of tumor suppressor proteins (Bieda et 
al., 2006), a variant affecting E2F-1 could have many extended effects on a number of 
proteins and genes.  Furthermore, a study aimed at identifying all binding sites of E2F-1 used 
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chromatin immunoprecipitation chip (ChIP-chip) analysis to show that E2F-1 binds to more 
than 20% of all human promoters (Bieda et al., 2006).  It was suggested that E2F-1 is 
involved in the regulation of a large fractions of genes and therefore variants affecting this 
factor could have many implications. 
Finally, network analysis of the genes predicted to be affected by rs200981 using 
GeneMANIA revealed association with functions such as “nucleosomes”, “DNA bending 
complex”, “DNA packaging complex”, “nucleosome assembly”, “chromatin assembly” and 
“protein-DNA complex assembly”, amongst others.  These findings are in accordance with a 
recent study that suggested that aberrations in common underlying molecular processes were 
involved in schizophrenia susceptibility (Luo et al., 2013).  This study used the top 
schizophrenia susceptibility genes identified to date and performed protein-protein interaction 
network analysis on the proteins encoded by these genes.  Additionally, the findings were 
subsequently confirmed using transcriptome data from a clinical sample.  The highly 
interconnected protein network identified in this study highlighted that top schizophrenia 
susceptibility genes are involved in common fundamental molecular processes.  This might 
also explain the heterogeneous nature of schizophrenia and the fact that that many different 
pathways have been associated with the disorder (Luo et al., 2013).   
Two more variants, namely rs200485 and rs200483, which were also among the top 10 
regulatory polymorphisms affected the binding of many of the same proteins, but the one that 
is probably most important is DNA-directed RNA polymerase II subunit RPB1 (POLR2A).  
The POLR2A gene codes for the largest subunit of RNA polymerase II, which is crucial for 
mRNA synthesis – a fundamental process in the human body.  Both rs200485 and rs200483 
appeared to affect the same histone protein genes associated with the extended MHC region 
as rs200981 – and were also in LD with the same two lead SNPs as mentioned above 
(rs17693963 and rs13211507).  Even though rs200485 and rs200483 are located within 1000 
bp of each other, these two SNPs are not only located very far from rs200981, but also the 
associated lead SNPs rs17693963 and rs13211507 (refer to Table 3.3 for distances in bp).  
This highlights the importance of analysing variants that occur in LD with GWAS findings, 
instead of merely looking at nearby variants or genes. 
The significance of the second most important variant, rs886424, was two-fold.  Not only did 
this SNP have a very high RegulomeDB score (1b), but it is a lead SNP from a previous 
GWAS.  This SNP affects human leukocyte antigen (HLA) genes as well as other genes such 
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as valyl-tRNA synthetase 2, mitochondrial (VARSL) and butyrophilin, subfamily 3, member 
A2 (BTN3A2) which are also located in the MHC region.  The variant also overlapped with a 
ChIP-seq peak for POLR2A, drawing attention to this factor once again.  Additionally, the 
10
th
 most significant variant on the list, rs1059612, occurs in LD with rs886424 and was 
predicted to affect HLA-A, which highlights the importance of this variant as well as the 
involvement of HLA genes and possibly the immune system in schizophrenia susceptibility.  
Furthermore, rs1059612 also overlapped with ChIP-seq peaks for CCCTC-binding factor 
(CTCF) and RAD21, which recently received strong support with regards to association with 
schizophrenia susceptibility (Juraeva et al., 2014).  These two factors are known to interact, 
particularly in neurons (Guo et al., 2012; Monahan et al., 2012).  The significance of CTCF 
is that it is a transcriptional regulator that modulates chromatin changes and has been shown 
to be a key regulator of neuronal differentiation (Phillips and Corces, 2009; Hirayama et al., 
2012).  Oddly enough, rs1059612 and rs886424 were not predicted to affect any genes 
according to the findings of rSNPBase, despite the strong evidence given by RegulomeDB.  
Though, this does not mean that these two variants are not involved in schizophrenia 
susceptibility.  Considering the available tools that can be used to assess the regulatory 
potential of a variant and the fact that these tools are still in their infancy (and constantly 
updated), it is possible that the link between rs1059612 and rs886424 and a known gene 
could have been missed. 
The last significant SNP on chromosome 6 was rs3094071, which occurred in LD with two 
SNPs previously identified in two separate GWAS, namely rs2523722 and rs2021722.  Once 
again, there was no functional evidence to support the association of either of these two SNPs 
with schizophrenia in the previous studies, however the findings of this study indicated an 
overlap between rs3094071 and an eQTL for HLA-A.  Additional supporting evidence for 
rs3094071 include an overlap with a high-mobility group (HMG) box transcription factor 1 
(Hbp1) DNase footprint region as well as overlaps with ChIP-Seq peaks for TFAP2A, 
TFAP2C, JUN, JUND and EP300.   
Besides the variants on chromosome 6, there were also significant regulatory polymorphisms 
located on chromosomes 3 (rs2535629), 8 (rs16887343) and 19 (rs4808967 and rs4808203).  
Importantly, both variants on chromosome 19 occur in LD with the same SNP identified in a 
GWAS, namely rs2905424.  These two regulatory variants seemed to affect the same eQTL 
(ATP13A1, EDG4, KIAA0892), despite showing overlaps with different DNase footprint 
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regions and ChIP-Seq peaks.  This indicates that if these genes are indeed affected, it would 
most likely be due to a cumulative effect between these variants and not merely due to one 
SNP in one regulatory region.  Finally, rs2535629 and rs16887343 were predicted to affect 
genes such as inter-alpha-trypsin inhibitor heavy chain family, member 4 (ITIH4), 5'-
nucleotidase domain containing 2 (FLJ12442), WD repeat domain 51A (WDR51A), U6 
snRNA-associated Sm-like protein LSm1 gene (LSM1) and BCL2-associated athanogene 4 
gene (BAG4), which have previously been associated with schizophrenia (So et al., 2010; 
Ripke et al., 2011; Shi et al., 2011).   
 
3.5.2 Affected genes 
3.5.2.1 The HLA and histone protein genes 
Analysis of the genes potentially affected by SNPs in regulatory regions revealed that HLA 
genes were the most common targets according to RegulomeDB prediction, with HLA-A 
being affected by 26 different SNPs.  The HLA genes as well as the other genes potentially 
affected by the regulatory SNPs are listed in Table 3.4. 
Even though the first evidence linking this region to schizophrenia dates back as early as 
1974 (Cazzullo et al., 1974), the hypothesis of an immune component which contributes to 
schizophrenia susceptibility has gained more support through GWAS over the past few years 
(Debnath et al., 2013).  Chromosome 6p22.1 has consistently passed the genomewide 
significance threshold in several of these GWAS (Purcell et al., 2009; Shi et al., 2009; 
Stefansson et al., 2009).  However, the specific HLA variant(s) involved remain unclear.  
This is partly due to the vast number of genes located in this region as well as the blocks with 
variants in high LD (Sinkus et al., 2013).   
A recent study investigated the differences in expression levels of several HLA genes in the 
post-mortem hippocampus of individuals with schizophrenia and negative controls (Sinkus et 
al., 2013).  The selected genes all had potential brain specific functions and included MHC 
class 1 (MCH I) genes (HLA-A, -B, -C and –G) as well as MHC class II (MHC II) genes 
(HLA-DRA, -DQA1 and –DRB5).  MHCI molecules are expressed in nearly all cells and play 
a central role in the immune system.  Furthermore, these molecules are crucial for the 
maintenance of dendrites in the central nervous system (CNS) during development 
(Boulanger, 2009), and could possibly explain the link between schizophrenia and a 
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dysregulation in development.  Dendritic maintenance involves strengthening important 
synaptic connections while removing those that are defective (Shatz, 2002).  In the event of 
over-expression of the MHCI genes, excessive maintenance may be caused which could 
possibly explain the decreased density of dendritic spines observed in subjects with 
schizophrenia (Rosoklija et al., 2007; Shatz, 2002).  Additionally, MHCII proteins are 
involved in synapse maintenance and are expressed on microglia, which form part of the 
innate immune system in the brain (Gehrmann et al., 1995).  An increased expression of 
MHCII genes is associated with activated microglia, which is in accordance with elevated 
levels of activated microglia in individuals with schizophrenia (Rosoklija et al., 2007).  In 
addition to a role in development, MHC genes are also involved in synaptic plasticity in the 
adult brain.  Reduced synaptic function and dendritic spine density are both characteristics 
that have been associated with schizophrenia, thus supporting the association with MHC 
genes. 
The fact that HLA-A was predicted by RegulomeDB to be affected the most of all the HLA 
genes is supported by the findings of Sinkus et al. (2013), where HLA-A was found to be the 
most highly expressed MHCI gene in the post-mortem hippocampal tissue samples of 
individuals with schizophrenia.  These high levels of expression are supported by the 
FANTOM data, which indicated that HLA-A has high expression levels in the brain (162.48 
TPM).  Furthermore, variants affecting this gene have been implicated in several major 
independent GWAS, in different populations, which strengthens the support for the 
involvement of HLA-A in schizophrenia.    
Another significant HLA gene among the top 10 affected genes was HLA-DQA1, which is 
part of MHC II and has a central role in the immune system.  The main function of the HLA-
DQA1 protein is to present peptides from extracellular proteins.  A study by Shi et al. (2009) 
also implicated this gene in schizophrenia in a cohort consisting of European and African 
American individuals.  HLA-DRB1 has also been studied extensively in schizophrenia 
research.  The findings have been both positive and negative, with some studies indicating an 
association between this gene and schizophrenia susceptibility (Li et al., 2001; Wright et al., 
2001), while others have been unable to confirm this link (Halley et al., 2013).  However, this 
could possibly be due to the fact that different populations and samples sizes were used for 
each study. 
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As indicated by the findings of rSNPBase and GWAS3D, the histone protein genes of the 
extended MHC region appear to be strong candidates (based on frequency) for schizophrenia 
susceptibility.  Furthermore, three of the genes predicted to be affected, namely histone 
cluster 1 H2ah, H2ag and H4i (HIST1H2AH, HIST1H2AG and HIST1H4I) show extremely 
high levels of expression in the brain with 208.33, 208.33 and 594.76 TPM respectively.  
Variants affecting histones highlight the possibility of aberrant gene regulation in 
fundamental processes, such as DNA packaging, that could confer an increased risk for this 
disorder.  In the event that histone binding to DNA promoter regions would be affected, TF 
binding would also be affected and thereby hinder gene expression (Deutsch et al., 2008).  
Specifically with regards to schizophrenia, studies have shown abnormal nucleo-histone 
staining patterns in peripheral neutrophils of schizophrenia patients (Issidorides et al., 1975; 
Issidorides et al., 1978; Sharma, 2005).  Furthermore, a post-mortem study of the prefrontal 
cortex of schizophrenia cases and controls that looked at altered histone protein expression, 
concluded that even though there was no distinct association between these proteins and 
schizophrenia susceptibility, there were clear differences between histone protein expression 
in different subtypes of schizophrenia (Akbarian et al., 2005).  The interactions between 
histone protein genes on chromosome 6 are illustrated by the circle plot in Fig. 3.3.  As the 
name suggests, GWAS3D focusses on variants of GWAS and therefore the genes in Fig. 3.3 
are the closest genes to the variants identified in previous GWAS.  However, these genes are 
in LD with the histone protein genes identified in this study.  Once again this emphasizes the 
importance of identifying exactly which genes are affected by regulatory variants as opposed 
to merely identifying the closest genes.  The histone protein genes predicted to be affected 
most frequently by rSNPBase (HIST1H2AH, HIST1H2BK, HIST1H2AG, HIST1H2BJ, 
HIST1H4I) have all only been identified in one study  -  a GWAS linking chromosome 6 to 
schizophrenia susceptibility (Shi et al., 2009).  Considering the importance of these proteins 
and the severe implications that variants affecting these genes would have, further analysis of 
such variants would be warranted. 
Although the abovementioned study linked histone protein genes to schizophrenia 
susceptibility, the mechanism by which these genes could cause an increased risk for 
schizophrenia remains unknown.  Nonetheless, the link between histone disruption and 
schizophrenia susceptibility might point towards more than the involvement of aberrant gene 
regulation conferring an increased risk for the disorder.  Histones have a particularly 
important role in protection against infections - it can interfere with bacterial cell membranes 
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as well as gene expression in microbes (Kawasaki & Iwamuro, 2008).  It has been shown that 
histones neutralize bacterial endotoxins in human placenta, which furthermore supports the 
notion of disrupted immune function in individuals with schizophrenia, particularly early in 
development (Kim et al., 2002).  Finally, it is also known that there is a positive correlation 
between the incidence of autoimmune disorders and schizophrenia risk (Müller & Schwarz, 
2010).  
 
3.5.2.2 Other genes on chromosome 6 
The HLA genes were not the only genes located in the MHC region that was predicted to be 
affected.  The results indicated that BTN3A2, a gene located in the extended MHC region and 
belonging to the butyrophilin (BTN) family and immunoglobulin superfamily, could possibly 
be affected by 14 different regulatory polymorphisms.  The protein product of this gene, 
along with the proteins from the rest of the BTN family, plays an important role in T-cell 
responses during an immune response.  A study by Bamne et al. (2012) looked at immune 
factors specifically in African American individuals.  A total of five SNPs in the MHC region 
were significantly associated with schizophrenia, of which two occurred within BTN3A2 and 
one occurred in the 3’UTR of BTN3A2.  These results support the predictions of 
RegulomeDB and also indicate a possible gene involved in schizophrenia susceptibility in 
African individuals.   
 
3.5.2.3 Genes on chromosome 10 and 19 
One of the most significant genes affected by 18 variants in regulatory regions was USMG5 
on chromosome 10 - a gene with a critical role in the maintenance of ATP synthase in 
mitochondria (Meyer et al., 2007).  Furthermore, USMG5 is shown to have high levels of 
expression in the brain (Martens et al., 2006), which was confirmed by analysing FANTOM 
data for cell lines related to the brain in this study.  This gene showed some of the highest 
expression levels in the brain with an average of 223.82 TPM.  Importantly, USMG5 was 
recently associated in a large GWAS including European individuals (Ripke et al., 2013).  
However, it was not listed as one of the main findings, but rather as one of the genes in the 
genomic region defined by LD surrounding a different lead SNP.  This is a prime example of 
important findings that are overlooked in GWAS. 
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Additionally, CNNM2 was predicted to be affected by 24 different SNPs according to 
rSNPBase (Table 3.5).  Interestingly, even though this gene shows moderate expression in the 
brain (7.50 TPM) according to FANTOM data, this gene has been linked to schizophrenia 
susceptibility in a large GWAS of European individuals as well as a study including a Han 
Chinese population (Ripke et al., 2011; Guan et al., 2012).  Furthermore, both these studies 
suggested an association between the 5’-nucleotidase, cytosolic II gene (NT5C2) and 
schizophrenia susceptibility as well.  This gene was also among the top 10 affected genes 
(according to rSNPBase) and was predicted to be affected by 13 different SNPs (Table 3.5).   
Chromosome 19 harbours three of the genes predicted to be affected, namely MAU2 Sister 
Chromatid Cohesion Factor (KIAA0892/MAU2), endothelial differentiation, lysophosphatidic 
acid G-protein-coupled receptor, 4 (EDG4) and ATPase type 13A1 (ATP13A1).  KIAA0892 is 
crucial for association of the cohesin complex with chromatin during interphase.  This gene 
has an important role during sister chromatid cohesion and normal progression through 
prometaphase (Braunholz et al., 2012).  EDG4 is a lysophosphatidic acid receptor gene which 
codes for an important extracellular signalling molecule that is involved in common cellular 
processes such as calcium mobilization, cell survival and mitogenesis (Contos et al., 2002).  
Finally, ATP13A1 is involved in nucleotide binding, cation transport and 
adenylpyrophosphatase (ATPase) activity (Weingarten et al., 2012).  A study aimed at 
analysing developmental expression of ATPase mRNA in mice showed that genes belonging 
to this family might be of significance in the nervous system.  ATP13A1 was found to have 
high expression levels during organogenesis, while an isoform of this gene was shown to be 
highly significant during neuronal development (Weingarten et al., 2012).  It is important to 
note that none of these genes on chromosome 19 have been associated with schizophrenia.  
Furthermore, these genes are also involved in basic, common processes in the body, which 
points toward fundamental mutations that occur early during development, which could 
confer an increased risk for schizophrenia.   
Interestingly, even though there was not a consensus between the predictions of 
RegulomeDB and rSNPBase, the most frequently affected genes were located on the same 
three chromosomes (6, 10 and 19).  Chromosome 6 has long been a chromosome of interest 
for schizophrenia association studies; however the latter two chromosomes have only 
recently gained more interest. 
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3.5.3 Pathway and network analysis 
At first glance, the terms in Cluster 1 of the DAVID pathway analysis seemed to be unrelated 
to schizophrenia despite high p-values for most of the terms in the cluster.  However, 
following a literature search of the top terms, links with schizophrenia became more 
apparent.  For example, the first two terms namely “Allograft rejection” and “Graft-versus-
host disease” is mainly due to an immune response by the body and has previously been 
linked to schizophrenia in a study that analysed variants that support the autoimmune 
hypothesis of schizophrenia (Carter, 2011).  Importantly, most of the pathways enriched for 
the selected genes were identified in this study as well.  Furthermore, processes such as 
“Allograft rejection” and “Graft-versus-host disease” support previous findings of increased 
episodes of psychosis following kidney and liver transplantations (Abbott et al., 2003; 
Goralczyk et al., 2010).   
Even though a number of studies have focussed on the overlap between type II diabetes and 
schizophrenia, very few studies have focussed on type I diabetes (KEGG p-value = 1.22E-
08).  In a nationwide study conducted in Finland, it was shown that individuals with 
schizophrenia had a decreased incidence of type I diabetes, although the genetic mechanism 
of this phenomenon was not explored (Juvonen et al., 2007).  In this study however, the 
overlap between these two disorders appeared to be due to the HLA genes (HLA-DQB1, 
HLA-DRB1, HLA-A, HLA-DRB5, HLA-C, HLA-DPB1, HLA-DQA1, HLA-G, HLA-DRA), 
which were all involved in the “Type I diabetes mellitus” pathway. 
Importantly, the pathway for cell adhesion molecules (CAMs) was enriched for 10 genes, 
with a p-value of 2.18E-04.  Neural CAMs are critical for processes such as neurulation, 
axonal outgrowth and neuronal connectivity during neurodevelopment.  Postmortem 
examination of schizophrenia cases and controls indicated that the expression of the 
embryonic form of neural CAMs was decreased in individuals with the disorder and was 
suggested to alter synaptic plasticity in schizophrenic brains (Barbeau et al., 1995).  This 
once again supports the hypothesis that schizophrenia might be a neurodevelopmental 
disorder. 
Furthermore, even though viral myocarditis was indicated to be enriched for a subset of the 
query genes (n = 9; p-value = 1.38E-05), this pathway has not previously been associated 
with schizophrenia.  However, myocarditis due to long-term clozapine treatment, which is an 
atypical drug used to treat schizophrenia, is known to occur (Lang et al., 2008).   
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The findings for the involvement of natural killer (NK) cells in schizophrenia have been 
inconsistent.  While there is strong evidence linking these cells with the disorder, the exact 
mechanism is still being debated.  McDaniel et al. (1992) showed that there was no 
difference in NK cell activity between schizophrenia cases and controls.  While Yovel et al. 
(2000) and Vodjgani et al. (2005) managed to show that there was an increase in NK cell 
activity among individuals with schizophrenia, DeLisi et al. (1983) and Abdeljaber et al. 
(1994)  successfully proved that NK cells were suppressed in individuals with the disorder.  
Additionally, low NK cell activity has also been observed in autism, a disorder that 
significantly overlaps with schizophrenia (Vojdani et al., 2008).  Either way, NK cells are 
critical to the innate immune system and specifically respond to microbial infections (Farag 
& Caliguiri, 2006).  Therefore, these findings still support the hypothesis that schizophrenia 
is a pathogenic autoimmune disorder. 
Finally, network analysis indicated that two networks might be of importance, namely “ER to 
Golgi transport vesicle membrane” and “antigen processing and presentation of exogenous 
peptide antigen”.  The first network has appeared during pathway analysis of schizophrenia in 
two previous studies, however no strong associations were established (Lee et al., 2013; 
Purcell et al., 2014).  In contrast to this, numerous pathway studies showed an enrichment for 
antigen processing pathways presentation among schizophrenia associated genes (Fellerhof 
and Wank, 2009; Xu et al., 2012; Aberg et al., 2013; Luo et al., 2013).  In fact, in a study that 
used RNA-Seq analysis to link dysregulation of the immune system to schizophrenia, 
“antigen processing and presentation” was the most enriched pathway in 218 differentially 
expressed genes (Xu et al., 2012).  Once again, this ties previous findings as well as the 
findings of this study to an immune response conferring an increased risk for schizophrenia.   
Analysis of co-expressed genes within GeneMANIA indicated that many of the HLA genes 
are expressed together.  However, the ubiquitin C gene (UBC) was co-expressed with a 
number of HLA genes as well as the Solute Carrier Family 3 (Amino Acid Transporter 
Heavy Chain) Member 2 gene (SLC3A2) and the heat shock protein 90kDa alpha (cytosolic), 
class B member 1 gene (HSP90AB1) (Fig. S1).  Furthermore, analysis of genetic interaction 
data indicated that UBC interacts with coagulation factor II (F2) as well as nuclear factor of 
activated T-cells, cytoplasmic, calcineurin-dependent 2 (NFATC2) (Fig. S1).  The importance 
of UBC is that it is a critical “switchboard” gene, which has shown to be involved in a 
number of diseases.  In a study by Lee et al. (2011), UBC was abnormally expressed in 
samples from individuals with schizophrenia and was shown to interact with marker genes of 
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schizophrenia, bipolar disorder and major depression.  Variants affecting this gene could 
therefore explain the overlaps that are often seen in the genetics of these disorders.  Finally, 
FANTOM data showed the highest expression levels for UBC compared to the other genes 
identified in this study, with an average expression of 811.89 TPM in the brain.  These 
expression levels are extremely high and would warrant further attention in future studies. 
Additionally, an HLA gene was once again the most significant, with HLA-DRB5 shown to 
interact with the most genes.  This gene was also part of the “antigen processing and 
presentation of exogenous peptide antigen” network.  While there is no evidence supporting 
the role of HLA-DRB5 in schizophrenia, this gene has been identified as a candidate 
susceptibility gene for Alzheimer’s disease (Lambert et al., 2013).  It is known that there are 
many significant genetic overlaps between schizophrenia and Alzheimer’s disease (Farooqui 
et al., 2013), which might indicate that there are many common genes that are yet to be 
identified.  While there may be not evidence linking this gene to schizophrenia, the “antigen 
processing and presentation of exogenous peptide antigen” network support the notion of 
immunity playing a role in schizophrenia.  More importantly, this network has also been 
associated with schizophrenia in previous studies (Xu et al., 2012; Aberg et al., 2013; Luo et 
al., 2013), suggesting a significant dysregulation in this network that could confer an 
increased risk for schizophrenia. 
The hypothesis that schizophrenia might be an autoimmune disease was first conceived in the 
early 1960’s (Burch, 1964).  Circumstantial evidence that point towards autoimmunity 
include the presence of an autoimmune disorder in many individuals with schizophrenia, 
association with the MHC region and improvement of psychotic symptoms with 
immunosuppression (Jones et al., 2005).  This hypothesis has been strongly criticized due to 
the widely held belief that autoantibodies would not be able to cross the blood-brain barrier to 
the nervous system (Jones et al., 2005).  However, it is possible that infectious agents can 
cross this barrier and invade the central nervous system directly (Benros et al., 2012).  
Additionally, it is also possible that inflammation and infection can affect the brain through 
many different pathways and interactions (Benros et al., 2012).  Further support for this 
hypothesis is that it might explain the high rate of perinatal obstetric complications observed 
among individuals with the disorder (Kirch, 1993).  However, the exact etiological 
mechanism through which schizophrenia and autoimmune responses overlap is still 
unknown.  It is suggested that the HLA and histone protein genes identified in this study 
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might have a role in an autoimmune response.  Though, it is unlikely that these genes act in 
isolation and the interactions would therefore need considerable attention. 
The limitations of this study lie within the tools used.  Even though bioinformatics provide 
endless possibilities for the discovery and analysis of disease-associated variants, the tools 
used for analysis of non-coding regions could be considered to still be in an early 
developmental phase, compared to most other tools.  This means that many significant 
findings could possibly have been overlooked.  Additionally, there is not always consensus 
among the results of different tools, making it difficult to distinguish between results that are 
not significant and results that were potentially missed, but are still significant.  Furthermore, 
despite the power of bioinformatic tools, it is still not possible to predict the exact 
mechanisms by which a variant or group of variants exactly affect the regulation and 
expression of a gene.  Even though it is possible to link variants to various regions, it would 
be crucial to understand the detailed mechanism by which gene expression is affected in 
order to understand the association with specific disorders. 
Finally, one of the biggest hurdles specifically in the context of this study is the fact that most 
of these findings would be applicable to individuals of European or Asian descent, since the 
original GWAS findings used for the initial analyses were from studies that included 
individuals from these populations.  It would therefore be essential to study these variants in 
an African population as well. 
 
3.6 CONCLUSION  
The significance of this study is two-fold.  Firstly, functional evidence was provided for 
genomic regions that have previously been linked to schizophrenia by GWAS.  This was 
achieved by analysing variants with regulatory potential and the effects that these variants 
might have.  Many of the findings of previous GWAS have been linked to schizophrenia, 
despite functional evidence to support the findings.  However, this study was able to show 
that in many cases there was evidence supporting the association of variants in LD with 
GWAS SNPs to schizophrenia susceptibility.  Secondly, novel findings of this study include 
the identification of three genes on chromosome 19 (KIAA0892, EDG4 and ATP13A1) that 
were affected by a number of SNPs in regulatory regions, as well as the regulatory variant 
rs200981 on chromosome 6 that might be implicated in schizophrenia susceptibility.  Finally, 
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although the identification of the histone protein genes that could be affected in schizophrenia 
were not novel, these genes have not been studied extensively and would require further 
attention. 
Throughout this study, evidence was gained for a multitude of regulatory factors that could 
be involved in schizophrenia susceptibility.  However, the pieces if this intricate puzzle still 
need to be put together.  This will only be possible with the continuous development of 
bioinformatics tools in conjunction with experimental studies.  The findings of this study 
point towards mutations that occur during early stages of development in pathways related to 
fundamental processes in the human body.  This was illustrated by variants shown to affect 
essential genes and regulatory elements, such as the histone protein genes in the extended 
MHC region, which are crucial for transcriptional regulation, DNA repair and factors such as 
POLR2A which is crucial for mRNA synthesis and finally EP300, which is essential for 
normal development before and after birth.  Further evidence pointing towards aberrant 
regulation of higher level processes, was that the sTRAP results corresponded largely 
between schizophrenia as well as the control disorders/traits.  However, there seemed to be a 
substantial amount of evidence linking immune function and neuronal development to 
schizophrenia.  It is possible that both of these events are crucial: while mutations in neuronal 
development could confer an increased risk for schizophrenia, an aberrant immune response 
could lead to onset of this disorder.  Therefore, it is suggested that these two processes should 
be studied together, rather than in isolation.  Additionally, the possibility that DNA packaging 
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INVESTIGATION OF REGULATORY POLYMORPHISMS IN 
SCHIZOPHRENIA SUSCEPTIBILITY IN A                                              
SOUTH AFRICAN XHOSA COHORT 
 
4.1 ABSTRACT 
Despite the value of this cohort, the South African Xhosa population has been significantly 
underrepresented in psychiatric genetic studies.  This study aimed to serve as a proof of 
concept of the validity of the regulatory variants identified by means of bioinformatic 
analyses in schizophrenia susceptibility in a Xhosa cohort of 100 cases and 100 controls.  Six 
SNPs with high regulatory potential as well as four corresponding SNPs from previous 
GWAS (which occurred in LD with the regulatory SNPs) were selected for genotyping.  
PCR-RFLP was used for genotyping, while bi-directional Sanger sequencing was used to 
confirm the functionality of the assay.  Statistical analyses were performed with SNPStats 
and R statistical packages.  Even though no single SNP was significantly associated with 
schizophrenia susceptibility, two haplotypes of regulatory variants (rs200483-rs200485-
rs2517611; p = 0.0385 and rs200981-rs2517611-rs3129701; p = 0.041) were significantly 
associated with risk for the disorder in this cohort.  These haplotypes were predicted to affect 
DNA packaging.  A further two haplotypes were associated with positive symptoms, while 
two regulatory SNPs (rs2535629; p = 0.0325 and rs2517611; p = 0.0456) were significantly 
associated with negative symptoms.  It is hoped that these results as well as the findings of 
future studies could act in conjunction with GWAS to uncover the mechanisms by which 
common variants in regulatory regions contribute to schizophrenia susceptibility. 
 
4.2 INTRODUCTION 
Despite the decades of research and different approaches that have been used, the aetiology 
of schizophrenia still eludes researchers.  In a series of articles published in Nature in April 
2014 (Volume 508, Issue 7494), it is clear that despite the multitude of studies and significant 
findings thus far, schizophrenia remains a complex and devastating disorder.  Since 2011, 
more than 100 genome-wide significant hits associated with almost 700 genes have been 
identified (Wright, 2014).  However, with each association, more unresolved questions 
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emerge, making research efforts seem like an infinite loop.  The most recent and largest 
schizophrenia GWAS to date was recently published by the PGC and provided irrefutable 
evidence for the genetic contribution to schizophrenia.  A staggering 108 loci were associated 
with the disorder, of which 83 were novel (Ripke et al., 2014).  Two of the most significant 
findings of this study were firstly, the association of DRD2 which codes for the dopamine 
receptor DRD2 and has therapeutic relevance and secondly, the association of the MHC 
region (as well as genes outside of this region, but with an immune function) that support the 
hypothesis of aberrant immune responses in schizophrenia (Ripke et al., 2014).  The findings 
of this study are an indication of the sheer size of psychiatric genetics and the progress being 
made.   
Initially, the promise of GWAS seemed endless.  The first GWAS, performed in 2005, 
screened for 116 204 SNP in 96 cases and 50 controls in a study of age-related macular 
degeneration (Klein et al., 2005).  Since then, GWAS have increased substantially in power 
and size.  Between 2005 and 2012, more than 1000 GWAS, replication studies and meta-
analyses were published, with the promise of personalised therapy in the near future.  
However, in the last few years, it has become clear that GWAS is not necessarily the best 
approach for genetic studies of complex disorders.  In a review by Klein et al. (2012), three 
important factors of GWAS were assessed, namely sample size, sample characterization and 
effect size.  While it is generally thought that bigger sample sizes lead to more accurate 
findings, large GWAS tend  to be successful at identifying many variants with small effect 
sizes, with the majority of odds ratio values around 1.  Finally, regarding sample 
characterization, it is possible that individuals with symptoms of one disorder could 
wrongfully be included in a study that analyses a completely different disorder.  Another flaw 
of GWAS is that due to the extensive corrections and stringent thresholds for significance, 
many variants with small effects can easily be missed (Sadee et al., 2014).  When studying 
complex psychiatric illnesses, the question arises whether studying something as simple as 
SNPs could provide clues to the intricate nature of the disorder.  In a study that tested the 
polygenic model of schizophrenia, the conclusion was that approximately one third of the 
heritability observed in the disorder can be attributed to the cumulative effect of hundreds or 
thousands of common SNPs (Purcell et al., 2009).  While the significance of SNPs is 
undoubted, it is more accurate to assume that many of these nucleotides along with copy 
number variations in a specific pathway(s) would interact to cause a disorder such as 
schizophrenia.  Furthermore, these causal networks would have to be studied in multiple 
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populations in order to clarify what leads to susceptibility of a disorder worldwide.  However, 
the point is not to discredit the validity of GWAS, but rather to focus on the additional studies 
that need to be done, such as identifying rare variants with large effect sizes, variants in 
regulatory regions and performing pathway and network analyses.  Finally, GWAS tend to 
include individuals of European or Asian descent and no GWAS regarding schizophrenia has 
included African individuals to date (with the exception of African American individuals).  
This leaves a considerable gap in understanding the disorder as well as effective treatment for 
all ethnicities. 
One such group that has been overlooked in genetic studies is the South African Xhosa 
population.  Xhosa individuals form the second largest indigenous African group in South 
Africa (Statistics South Africa, 2013).  This group is considered to be culturally and 
genetically homogenous, due to geographical influences and therefore provide valuable data 
for genetic research (Le Roux et al, 2007).  Additionally, it would also be extremely 
important to study genetic variation among the other populations within Africa.  As indicated 
by May et al. (2013), there are distinct genetic differences between the southern African 
Bantu speakers and the Yoruban and Luhya populations from western and central Africa 
respectively, indicating that the inclusion of only one or a few African populations would not 
be sufficient to capture the entirety of genetic variation among all the various African 
genomes. 
Therefore, the aim was to perform a pilot study using a small cohort of South African Xhosa 
cases and controls to address two issues of current research: firstly to genotype selected 
variants in regulatory regions of the genome instead of variants in protein-coding genes and 
secondly, to use a cohort of South African Xhosa individuals to fill the void regarding the 
inclusion of these individuals in genetics studies.  Finally, genotyping the variants identified 
by bioinformatics analyses in Chapter 3 was particularly important since it is usually 
recommended that bioinformatics results be validated with experimental work (McInerney, 
2002; Fernandes et al., 2012). 
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4.3 MATERIALS AND METHODS 
4.3.1 Patient Samples 
A subset of 100 Xhosa schizophrenia patients, which form part of a larger cohort of South 
African Xhosa patients recruited from various in- and outpatient hospital services and clinics 
in the Western Cape, was used.  The two selection criteria that were used to choose 
individuals included (1) diagnosis with schizophrenia according to the DSM-IV and (2) all 
four grandparents of each individual had to be of Xhosa ancestry.  Patients were also assessed 
with comprehensive tools, including the Diagnostic Interview for Genetic Studies version 2 
and the SANS and SAPS.   The age of the schizophrenia cases ranged between 13 and 51 
years of age, with the average age being 24.  Regarding gender, 77% of the cases were male 
and 23% female.  Due to mutual cultural and environmental backgrounds, this group is 
clinically homogeneous, and therefore provides valuable data for the improved understanding 
of genetic factors in African schizophrenia patients.  A subset of 100 unrelated healthy Xhosa 
controls, which are also part of a larger group, was available and were matched for age and 
gender.  Genomic DNA (gDNA), extracted from whole blood using the Miller et al. (1988) 
method, was available for each patient and control individual.  This project forms part of a 
larger long-term study, Genetics of Schizophrenia, for which ethical approval was obtained 
from the Stellenbosch University Human Research Committee (Reference number: 
1907/005- and 2001/050).  Informed written consent was obtained from all individuals or, 
where necessary, the primary caregivers.   
 
4.3.2 Genotyping 
4.3.2.1 SNP Selection 
Based on the bioinformatics analyses in Chapter 3, ten SNPs were selected for genotyping in 
the South African Xhosa cohort to determine whether any of the regulatory SNPs or 
corresponding SNPs from previous GWAS are associated with schizophrenia susceptibility in 
this cohort.  Six SNPs, based on high regulatory potential (indicated by RegulomeDB scores) 
and the four corresponding SNPs from the original GWAS that occurred in LD with these six 
SNPs were selected for genotyping (Table 4.1).  The majority of the SNPs are on 
chromosome 6, with the locations indicated in Fig. 4.1.   
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Table 4.1. SNPs selected for genotyping. The regulatory SNPs correspond to and occur in 
LD with the original SNPs from GWAS.  
GWAS SNP Chromosome Regulatory SNP RegulomeDB Score 
rs17693963 
rs13211507 
 rs200981 1a 
6 rs200485 1b 













4.3.2.2 Primer Design 
Primers had to be designed for all but one SNP, rs2021722, which had been designed prior to 
this study (Coffee, 2012).  The primers used for amplification of the regions containing the 
SNPs in regulatory regions as well as the corresponding SNPs from previous GWAS (in the 
event that a regulatory variant is a SNP in LD with a SNP from a GWAS) are summarized in 
Table 4.2.  All the primers were designed using PrimerQuest and analyzed using 
OligoAnalyzer (Integrated DNA Technologies Inc., 2012).  Subsequently, the primers were 
synthesized by Integrated DNA Technologies (Integrated DNA Technologies, Inc., Iowa, 
USA). 
 
4.3.2.3 PCR Optimization 
All reactions, except for rs2021722, had to be optimized.  For optimal amplification by PCR, 

































































































































































Figure 4.1. The locations of the selected SNPs on chromosome 6. The figure is 
not drawn to scale. 
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, California, USA) to determine optimal temperature by performing a 
gradient PCR and the GeneAmp
®
 PCR Systems 2700 (Applied Biosystems
TM
, California, 
USA) for further optimization and final PCR reactions.  Reagents were supplied by Bioline 
(Bioline
TM
, London, UK) and Kapa Biosystems (Cape Town, South Africa).  All PCR 
reactions were performed using 30 ng DNA, 1X reaction buffer, 1.5 mM MgCl2, 0.4 µM 
dNTPs and 0.5U BIOTAQ Polymerase, with a total reaction volume of 25 µl.  For all 
reactions, 0.4 µM forward primer and 0.4 µM reverse primer were used, with the exception 
of the amplification of the amplicons for rs17693963 and rs2021722 which used 0.2 μM of 
each primer.  In order to amplify the region for SNP rs200981, 4 μl Betaine (Sigma-Aldrich 
(Pty) Ltd, Aston Manor, South Africa) was required in each reaction.  Due to non-specific 
amplification, KAPATaq Ready Mix (Kapa Biosystems, Cape Town, South Africa) was used 
for SNP rs200483.  For this analysis, the amount of reagents were used according to the 
Standard PCR Protocol for 20 μl reactions (10 μl ReadyMix with Mg
2+
, 0.4 μM forward 
primer, 0.4 μM reverse primer, 30 ng DNA template and 7.4 μl water).  
 
The reaction cycles for all amplifications consisted of an initial denaturation at 94°C for 3 
minutes; followed by varying 40 cycles (except for rs200483 which used 35 cycles) of 
denaturation at 94°C for 15 seconds, annealing at the respective melting temperatures (Tm, 
indicated in Table 4.2) for 15 seconds and extension at 72°C for 30 seconds; concluding with 
a final extension step at 72°C for 5 minutes.  Thereafter, each amplicon (mixed with 5 μl 
Cresol loading dye) was loaded onto a 1.5% (w/v) agarose gel stained with 0.5 g/ml 
ethidium bromide to facilitate visualisation.  Electrophoresis was performed in 1X sodium 
borate (SB) buffer at 200 V for 25 minutes.  Additionally, a 100 bp molecular weight marker 
(Hyperladder IV, Bioline
TM
, London, UK) was loaded to determine the sizes of the amplified 
fragments.  Finally, the fragments were visualized under an ultra-violet light with the Bio-
Rad Molecular Imager
®
 Gel Doc™ XR+ System with Image Lab™ v5.1 Software (Bio-Rad 
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Table 4.2. The forward (F) and reverse (R) primers and reaction conditions that were used to 







Primer Sequence (5’-3’) 
rs17693963 630 65 
F: CTGGCTATCAAGAGCGAAACT 
R: TCACGTTGGTCTGAGGAAAC 
rs200483 498 58 
F: GCGATCTCAGCTCACTGTAAA 
R: GAGCATCCACGGGTTTCTAA 
rs200485 358 60 
F: CGCTTCTTGCCATCCTTCTT 
R: AGCTGTGCGATTGGCTTAC 
rs200981 327 65 
F: GGGATAATGCGGGTCTTCTT 
R: CGCGCCCAGTATTGACTATAA 
rs13211507 303 65 
F: CCACCACCAGACACATCTTAC 
R: CTGGTCTCAAACTCCTTGTCTC 
rs2517611 379 60 
F: CGGGTTGAGGTGATTGATTCT 
R: CCAACTGGAAGCACTAATGGA 
rs2021722 678 62 
F: TACTCCATTTAAGGGCTCCTGGGT 
R: GGAGATCCTAAGTCAGTTGGTCTAGGT 
rs3129701 676 60 
F: GGGTGTGAGCAGTGGAAATA 
R: GGAATCCTGGTCTGTGTTCTT 
rs2535629 484 58 
F: GGTGCTGATTACCTGCTCTAA 
R: TGTACAGACTCCCTCCTCAA 





4.3.2.4 PCR-RFLP Genotyping Assays 
All SNPs were genotyped by means of PCR-RFLP, using the restriction enzymes identified 
by RestrictionMapper v.3 (RestrictionMapper, 2009) and “In silico Simulation of Molecular 
Biology Experiments” (Bikandi, 2004) (Table 4.3).  In all instances, restriction enzyme 
digests were performed using the amounts of PCR product, restriction enzyme and where 
necessary BSA, as indicated in Table S5.  The respective incubation times and temperatures 
for each SNP are indicated in Table 4.3.  Once the restriction enzyme digests were 
completed, the resulting fragments were separated by electrophoresis on the appropriate gel 
(Tables 4.3, S5).   
The resulting digest product did not need to be mixed with loading dye in the case of 
FastDigest enzymes, since the FastDigest Green Buffer was used, which allows direct loading 
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of the product onto gels.  However, in all other instances, 10 μl cresol loading dye was added 
to 20 μl of digest product and loaded onto the gel.  The gels were stained with 0.5 g/ml 
ethidium bromide and electrophoresis was performed in a 1X SB buffer at 160 V for the 
appropriate time (Table 4.3).  A 100 bp molecular weight marker (Hyperladder IV, 
Bioline
TM
, London, UK) was also loaded onto each gel to determine the sizes of the amplified 
fragments.  In order to visualize the fragments, the Bio-Rad Molecular Imager
®
 Gel Doc™ 
XR+ System with Image Lab™ v5.1 Software (Bio-Rad Laboratories, Inc., California) was 
used. 





















374, 245, 11 
266, 245, 108, 
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3% agarose 
1 h 30 min 













109, 106, 86 
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40 min 
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299, 132, 53 
3% agarose 
40 min 









The reference allele is listed first. 
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4.3.2.5 Bi-directional Sanger sequencing 
To ensure the functionality of the genotyping assay, bi-directional Sanger sequencing was 
performed to confirm sample genotypes.  PCR products of two samples (one homozygote and 
one heterozygote) for each SNP were purified using the SureClean protocol (Bioline
TM
, 
London, UK; Appendix 5).  Once the samples were cleaned, the concentrations of the 
purified product were measured using the Nanodrop spectrophotometer (NanoDrop
®
 ND-
100, Nanodrop Technologies Inc., Wilmington, Delaware, USA) at a wavelength of 260 nm.  
Thereafter, the sequencing reaction was performed as described in the Big Dye
®
 Terminator 
v3.1 Cycle Sequencing Kit Manual (Applied Biosystems
TM
, California, USA; Appendix 5).  
The samples were then analysed using capillary electrophoresis at the Central Analytical 
Facility, Stellenbosch University on a 3130XI Genetic Analyzer (Applied Biosystems
TM
, 
California, USA).  Once bi-directional sequencing was completed, the presence of the SNP 






4.3.3 Statistical & Bioinformatic Analyses 





http://osse.bii.a-star.edu.sg/; Accessed September 2014) was used to determine the power of 
this study, given the sample size and allele frequencies.  In order to calculate the range of 
power, calculations were done with the two SNPs with the lowest and highest minor allele 
frequencies (MAFs), namely rs13211507 and rs2021722 respectively.  
Due to known genetic differences between various populations, the MAFs of the ten selected 
SNPs were compared to the allele frequencies observed in the CEU, YRI and CHB 
populations, using 1000 Genomes and HapMap data. 
For each genotyped SNP, descriptive statistics and Hardy-Weinberg equilibrium (HWE) 
analysis were done with SNPStats (Solé et al., 2006; 
http://bioinfo.iconcologia.net/SNPstats_web; Accessed September 2014).  This online tool 
allows for a convenient and accurate overview of all clinical and genotype data.  It 
implements R packages for statistical analyses (Solé et al., 2006).  The genotype and allele 
frequencies were determined in the Xhosa schizophrenia cases and controls.  Genotypes were 
tested for deviations from HWE and the p-value cut off was 0.01.  Remaining statistical 
analyses were performed in R (R Core Team, 2014), using the R packages genetics (Warnes 
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et al., 2013) and haplo.stats (Sinnwell & Schaid, 2013), to determine whether there was an 
association between any of the genotyped SNPs or SNP haplotypes and schizophrenia 
susceptibility.  Analyses were also done to determine possible associations between the 
genotyped SNPs / SNP haplotypes and negative or positive symptoms, using SANS and 
SAPS as well as the subgroups of these symptoms.  Logistic regression was used to model 
schizophrenia susceptibility, which is a dichotomous outcome, while general linear models 
were used for numerical data.  Confidence intervals, effects sizes and p-values were derived 
from the aforementioned models and associations with p-values < 0.05 were accepted as 
significant.  Allelic combinations and frequencies were modelled with functions from 
haplo.stats.  Modelling was used in order to avoid false positives and adjust for known or 
suspected confounding factors such as age and gender.       
Finally, all variants significantly associated with schizophrenia susceptibility were analysed 
with GeneMANIA to identify affected biological features, by performing network analysis 
for the predicted affected genes (http://www.genemania.org/; Accessed September 2014).  
The analysis was done similar to the description in section 3.3.9.  All features with a FDR < 
10
-5 
were accepted as significant.  This was only done for variants significantly associated 
with schizophrenia susceptibility, since this was the main focus of this project. 
 
4.4 RESULTS 
Statistical power of the study using OSSE, revealed power to detect significance was between 
16.8% and 20.7%, depending on the frequency of the SNP that was being investigated.  
These results were based on SNPs rs13211507 and rs2021722 which had the lowest and 
highest minor allele frequencies respectively and therefore gave an indication of the lowest 
and highest power to detect significance. 
The ten selected SNPs were successfully genotyped in the Xhosa cohort and bi-directional 
Sanger sequencing confirmed that the genotyping assay worked (Fig. S4).   
Comparisons of the MAFs of each SNP between the Xhosa schizophrenia cases and controls 
are illustrated in Fig. 4.2.  Additionally, comparisons of MAFs of these SNPs in different 
populations, using the 1000 Genomes and HapMap data are depicted in Fig. S3.  
Comparisons with these population data indicated distinct differences between the MAFs of 
the selected SNPs in the Xhosa cohort compared to MAFs in the CEU, CHB and YRI 
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populations.  The SNPs identified in previous GWAS, namely rs17693963, rs13211507 and 
rs4687552, were lower in the YRI and Xhosa populations that in the CEU population.    
 
 
Figure 4.2.  Minor allele frequencies of the genotyped SNPs in the South African Xhosa 
cases and controls.  The significant haplotypes associated with schizophrenia susceptibility 
are rs200483-rs200485-rs2517611 and rs200981-rs2517611-rs3129701. All the SNPs occur 
on chromosome 6, with the exception of the last two SNPs (rs2535629 and rs4687552) which 
are located on chromosome 3. 
 
Analysis of HWE revealed that all SNPs were in HWE.  When adjusted for age and gender, 
single SNP analysis indicated that no SNPs were significantly associated with schizophrenia 
risk.  However, two haplotypes were significantly associated with susceptibility for the 
disorder (Table 4.4).  Significant results of association analysis with negative symptoms are 
summarised in Table 4.5 and indicates that two single SNPs were associated with these 
symptoms.  In contrast to this, no single SNPs or SNP haplotypes were significantly 
associated with positive symptoms.   However, a significant single SNP association with the 
formal thought disorder subgroup of positive symptoms was identified (Table S4).  No 
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Table 4.4. Results of association analysis with schizophrenia susceptibility. 
Outcome SNPs / specific allele p-value Frequency OR 95% CI 
Schizophrenia 
Susceptibililty 















0.041 0.22 0.51 0.27 0.98 
 
 




Comparison p-value Effect 95% CI 
SANS rs2535629 Dominant TT versus CC+CT 0.0325 -0.456 -0.805 -0.106 
SANS rs2517611 Heterozygous CT versus CC+TT 0.0456 -0.453 -0.808 -0.098 
 
Finally, analysis of the genes affected by the two significant SNP haplotypes (rs200483-
rs200485-rs2517611 and rs200981-rs2517611-rs3129701) associated with schizophrenia 
susceptibility using GeneMania, implicated significant processes involved in DNA 
packaging, from DNA level to chromatin level, in schizophrenia susceptibility (Table 4.6).  
The most significantly affected feature was “nucleosome” for both of the haplotypes, with 
FDRs of 1.69 x 10
-15
 and 1.25 x 10
-13
. 




nucleosome 1.69E-15 1.25E-13 
DNA bending complex 1.69E-15 1.25E-13 
DNA packaging complex 3.75E-14 1.67E-12 
nucleosome assembly 4.45E-11 7.70E-10 
chromatin assembly 3.75E-10 4.90E-09 
nucleosome organization 1.32E-09 1.43E-08 
protein-DNA complex assembly 1.32E-09 1.43E-08 
chromatin assembly or disassembly 4.95E-09 4.53E-08 
DNA packaging 7.57E-09 6.51E-08 
protein-DNA complex subunit 
organization 
1.25E-08 1.00E-07 
DNA conformation change 3.06E-07 1.69E-06 
chromatin 7.55E-07 2.43E-06 
protein-DNA complex 1.05E-06 4.99E-06 
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The goal of this study was to genotype ten of the most significant variants (including the 
corresponding SNPs from previous GWAS) identified in the previous chapter, in a South 
African Xhosa cohort of 100 schizophrenia cases and 100 controls as a pilot study to validate 
the bioinformatics approach used.  As mentioned previously, there is currently a large void 
with regards to genetic studies that include African individuals.  The largest psychiatric 
GWAS to date, which was performed by the PGC, has provided valuable clues to the genetic 
architecture of schizophrenia, but predominantly included individuals of northern European 
descent (Ripke et al., 2014).  Yet, in order to improve and optimize treatments for individuals 
with schizophrenia worldwide, all populations would have to be represented in genetic 
studies – a major flaw that was recognised by the PGC itself (Reardon, 2014).   
As previously discussed, there are significant genetic differences between different 
populations.  Therefore, the MAFs of the genotyped SNPs were compared to the MAFs 
observed in the YRI, CEU and CHB populations according to 1000 Genomes and HapMap 
data.  Fig. S3 clearly indicates the differences observed between the African population and 
European and Asian individuals.  In most instances the allele frequencies observed in the 
African and/or Xhosa population differed significantly from the frequencies observed in the 
European and Asian populations.  Regarding SNPs rs17693963, rs13211507, rs2535629, 
rs4687552, rs3129701 the MAFS were much lower in the CEU and/or the CHB populations.  
It is well known that African genomes exhibit greater genetic diversity, less linkage 
disequilibrium between loci and extensive population substructure (Campbell & Tishkoff, 
2008).  Moreover, Africa has a complex population history due to the drastic variation in 
environmental factors and the adaptation of inhabitants to these factors.  This provides 
valuable information for genetic studies of disease susceptibility.  Furthermore, the Out of 
Africa model suggests that modern humans originated in Africa before migrating to other 
parts of the world (Tishkoff & Verrelli, 2003).  Nonetheless, to date only a small fraction of 
the ~2000 different ethno-linguistic groups in Africa has been included in GWAS.  In a study 
by Yu et al. (2002), the patterns of SNPs particularly in non-coding regions were analysed.  
Furthermore, the differences between patterns within Africans and between Africans and 
Eurasians were compared.  The average nucleotide diversity among African individuals was 
almost twice as high as what was observed among Europeans and Asians.  This clearly 
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indicates that Africans differ much more among each other than other populations and 
highlights the need for genetic studies in these groups.  
Once all of the variants were genotyped, analysis for HWE revealed that all SNPs were in 
HWE.  Single SNP analysis indicated that no SNPs were significantly associated with risk for 
the disorder, yet haplotype analysis identified two combinations of SNPs that were indeed 
associated with schizophrenia susceptibility (Table 4.4).  All of the SNPs involved in the two 
different haplotype combinations were regulatory SNPs (as determined by bioinformatic 
analyses in Chapter 3) and one of the combinations (rs200981-rs2517611-rs3129701; p = 
0.041; OR = 0.51; 95% CI = 0.27-0.98) contained the most significant SNP identified in the 
previous chapter, which was rs200981.  Importantly, none of these SNPs have been 
associated with schizophrenia susceptibility except for rs200483 and rs200981 (Nielsen et al., 
2014).  However, both these SNPs were only associated very recently (August 2014) in one 
other study and rs200981 was also identified as the most significantly associated variant 
(Nielsen et al., 2014).  Network analysis indicated that both haplotypes associated with 
schizophrenia susceptibility affected genes involved in functions such as “nucleosome”, 
“DNA bending complex”, “DNA packaging complex”, “nucleosome assembly”, “chromatin 
assembly” and “nucleosome organization” amongst others (Table 4.6).  These findings are in 
accordance with the findings of Luo et al. (2013), where genes involved in nucleosome 
assembly were significantly associated with schizophrenia susceptibility.  By modifying 
chromatin packaging, accessibility to gene promoters can be affected, which in turn can have 
extensive implications for gene regulation (Sharma et al., 2005).  Furthermore, chromatin 
remodelling is known to be particularly important during neural development and plasticity, 
which highlights the severity of abnormalities during this process (Hsieh & Gage, 2005; 
Lessard et al., 2007).  In fact, alterations in chromatin packaging could affect gene expression 
at every stage of neurogenesis (Hsieh & Gage, 2005).  This emphasizes the findings of the 
previous chapter, which pointed towards aberrant DNA packaging as well as affected histone 
protein genes, which might confer an increased risk for schizophrenia.  Furthermore, these 
findings also highlight the importance of focussing on gene regulation when studying 
complex disorders.  
Additional statistical analyses were aimed at identifying associations between any of the 
genotyped SNPs and negative or positive symptoms of schizophrenia based on SANS or 
SAPS.  This was particularly important considering the complications in schizophrenia 
diagnosis.  One of the many limitations of schizophrenia studies is that the disorder is usually 
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studied as a whole instead of focussing on the various endophenotypes (Greenwood et al., 
2013).  In fact, a recent study showed that schizophrenia is more likely a heterogeneous 
group of eight different inheritable disorders with distinct symptoms (Arnedo et al., 2014).  
While this study was not equipped to extensively study these endophenotypes, information 
regarding positive and negative symptoms was available for the Xhosa cases.  The positive 
symptoms which are measured by SAPS include delusions, hallucinations, formal thought 
disorder and bizarre behaviour, while negative symptoms measured by SANS include 
affective blunting, avolition/apathy, anhedonia/asociality, alogia and lack of attention 
(Andreasen, 1990).  Two SNPs, rs2535629 (p = 0.0325) and rs2517611 (p = 0.0456) were 
associated with negative symptoms based on a dominant and heterozygous inheritance model 
respectively Table 4.5).  Once again, both these SNPs were regulatory variants.  The 
importance of these findings is that negative symptoms are particularly difficult to treat.  
Therefore, by understanding which genetic variants (particularly regulatory variants) could be 
associated with these symptoms, this could aid in developing future research strategies to 
optimize treatments for these symptoms.  In contrast to this, there were no significant single 
SNP or SNP haplotype associations with overall positive symptoms of the disorder.     
In addition to associations with positive and negative symptoms, the subgroups were also 
used for analysis.  Interestingly, the top SNP (rs200981) was associated with a subgroup of 
positive symptoms, formal thought disorder (p = 0.0447; effect size = -0.59; 95% CI = -1.13-
(-0.05)), according to a heterozygous inheritance model (Table S4).  An association with 
formal thought disorder is particularly significant since this is one of central symptoms of 
schizophrenia (Wang et al., 2012).  Despite the prevalence of this symptom and the fact that 
twin and adoption studies have suggested that genetic factors might be involved, not many 
studies have focussed on the genetics of formal thought disorder (Levy et al., 2010).  To date, 
only one GWAS meta-analysis of this symptom has been performed with data from 
European-American individuals.  The study identified 61 SNPs associated with formal 
thought disorder with p < 10
-4 
(Wang et al., 2012) and supports the notion of genetic factors 
contributing to this symptom.   
None of the original SNPs identified by previous GWAS were significantly associated with 
schizophrenia susceptibility based on single SNP or haplotype analyses.  This once again 
emphasizes the importance of including different populations in genetic studies.  The original 
SNPs from GWAS, namely rs17693963, rs13211507, rs4687552, rs2021722 were identified 
in European individuals.  In all instances, the MAFs of these SNPs were lower in the YRI and 
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Xhosa population compared to the CEU population, except for rs2021722 which had a much 
higher MAF in the YRI population (Fig. S3).  This clearly shows that variants identified in 
these populations are not necessarily of importance for individuals of other ethnicities.  This 
also applies to the regulatory variants for which the MAFs differed significantly between the 
different populations and it is suggested that these SNPs be genotyped in additional 
populations as well. 
The lack of association between individual genotyped SNPs and schizophrenia susceptibility 
could be due to a number of reasons.  Firstly, it is possible that associations could not be 
detected due to the small size of the Xhosa cohort.  Secondly, as previously discussed, many 
of the MAFs (particularly of the SNPs identified in previous GWAS) were extremely low 
(Fig. 4.2).  Finally, considering the fact that the original SNPs identified in GWAS and the 
regulatory SNPs in LD with these SNPs were identified in European individuals, these SNPs 
would not necessarily be significant in an African population.   
Limitations of this study include the small sample size, validity of the diagnosed cases and 
controls as well as the fundamental understanding (and therefore the diagnosis) of 
schizophrenia.  Firstly, due to the small cohort size, this had implications for the power to 
detect significant associations.  It is therefore possible that significant associations with the 
genotyped SNPs could have been missed due to the lack of power of this study.  Nonetheless, 
it is possible to detect significant associations in small cohorts, as demonstrated by Shimada 
et al. (2000) in a study of acute myocardial infarction (AMI) in a cohort of 164 Japanese 
individuals (81 cases and 83 controls).  Despite the small cohort, an association was still 
identified between a SNP, C(-260) > T, in the promoter region of CD14 and AMI (p = 0.004; 
OR = 3.8).  This shows that smaller cohorts can successfully be used in association studies.  
Secondly, due to the current uncertainty surrounding the definition of the disorder as well as 
major overlaps in symptoms of other psychiatric illnesses, this has significant implications 
for diagnosis.  It is therefore possible, that a diagnosed individual might in fact suffer from a 
different, yet similar disorder.  Furthermore, individuals with psychosis are often not able to 
provide healthcare officials with a complete/accurate medical history (Duwe & Turetsky, 
2002).  There are numerous cases of patients being wrongfully diagnosed due to overlaps 
between symptoms of schizophrenia and other mental disorders.  For instance, psychotic 
bipolar disorder is often misdiagnosed as schizophrenia (Gonzalez-Pinto et al., 1998; Duwe 
& Turetsky, 2002).  This is even more common in individuals of African descent. 
Importantly, a study by Strakowski et al. (1996) determined that psychotic symptoms 
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reflective of schizophrenia were more frequently misdiagnosed in African American 
individuals than compared to Caucasians.  Finally, it is also a possibility that control subjects 
could develop the disorder at a later stage.  Still, considering that the prevalence of 
schizophrenia is approximately 1% in the general population, the chances of having such a 
control subject in the cohort would be rare.  Finally, due to the heterogeneous nature of 
schizophrenia, it would be more effective to study the genetic factors associated with the 
subtypes of schizophrenia, rather than looking at the disorder as a whole.  However, this 
seems to be a difficult situation: by understanding the genetics of the disorder, accurate 
diagnosis could be facilitated, but in order to study the genetics of schizophrenia subtypes, 
individuals would have to be carefully and accurately diagnosed in the first place.   
 
4.6 CONCLUSION  
This study successfully served as a pilot study to demonstrate the significance of regulatory 
variants in schizophrenia susceptibility and symptoms.  Furthermore, the findings validated 
the bioinformatic results of the previous chapter.  Statistical analyses significantly associated 
two haplotypes with schizophrenia susceptibility in a South African Xhosa cohort.  
Additionally, a number of SNPs and SNP haplotypes were significantly associated with the 
positive and negative symptoms of schizophrenia.  None of the genotyped variants that were 
identified in previous GWAS were significantly associated with schizophrenia susceptibility 
in this cohort, which proved (1) significant variants associated with a disorder in one 
population cannot necessarily be extrapolated to other populations and (2) in many instances 
the reported associated variant is in fact in LD with the actual variant of importance.  This 
study also highlighted the importance of verifying bioinformatic findings with experimental 
work, since not all variants identified in the previous chapter were significant in the Xhosa 
cohort.  However, it is possible that the identified regulatory variants could be significant in a 
larger Xhosa cohort or in a different population group.  Therefore, future work would require 
genotyping regulatory polymorphisms in a larger Xhosa cohort and ideally also other 
population groups.  Due to the positive results of this study, custom TaqMan® OpenArray® 
Genotyping Plates have been designed to genotype additional regulatory SNP (as identified in 
Chapter 3) in a larger cohort of Xhosa cases and controls. 
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CONCLUSION AND FUTURE DIRECTIONS 
 
The aim of this study was to establish and apply a bioinformatics pipeline for the 
identification of variants in regulatory regions and to validate these findings in a pilot 
association study.  The goal was successfully achieved by using two approaches.  The first 
part of the study included bioinformatic analyses and started by identifying significant SNPs 
from previous GWAS as well as SNPs that occur in LD with these variants.  The combined 
total of variants were annotated and analysed in terms of regulatory potential, using 
ENCODE data.  Variants were characterised using a series of predictive programs such as 
RegulomeDB, GWAS3D and TRAP, while affected genes were predicted using 
RegulomeDB and rSNPBase.  The expression of potentially affected genes in cell lines 
related to the brain was evaluated using FANTOM expression data.  Finally, pathway and 
network analyses were performed to provide a comprehensive overview of the processes 
affected by the implicated regulatory variants, using DAVID and GeneMANIA.  These 
analyses resulted in a bioinformatics pipeline that could theoretically be applied to the study 
of any disorder.  Many of the identified SNPs, predicted affected genes and implicated 
pathways and networks supported previous findings, particularly with regards to the 
involvement of immune functions and neurodevelopmental processes.  Additionally, many 
SNPs were novel findings and pointed towards the possible involvement of disrupted 
regulation during fundamental processes such as DNA packaging.  One such novel finding 
was rs200981 and was the most significant variant in terms of regulatory potential.  
Therefore, regarding the bioinformatic analyses, the aims of this study were  met.   
The second part of the study was important in order to validate the findings of the 
abovementioned bioinformatic analyses in a pilot association study.  For this association 
study a cohort of South African Xhosa cases and controls was chosen due to the fact that 
there is a large void with regards to the inclusion of African populations in schizophrenia 
genetics studies.  Furthermore, this population group is considered genetically homogenous 
and provides valuable genetic information.  The selected regulatory variants and 
corresponding SNPs from previous GWAS (with which these variants occurred in LD), were 
successfully genotyped in the entire cohort.  Statistical analyses of associations between 
genotyped SNPs / SNP haplotypes and schizophrenia susceptibility and symptoms identified 
a number of significant associations.  The most significant association was between two 
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haplotypes of regulatory variants (rs200483-rs200485-rs2517611 and rs200981-rs2517611-
rs3129701) and schizophrenia susceptibility.  Importantly, none of the SNPs that were 
previously associated with schizophrenia in GWAS of European individuals were 
significantly associated with schizophrenia in the Xhosa cohort.  This supported the notion 
that it is necessary to replicate significant findings in different populations.   
 
5.1 LIMITATIONS OF THIS STUDY 
While significant associations between the genotyped SNPs / SNP haplotypes and 
schizophrenia susceptibility as well as positive and negative symptoms were identified, a 
small cohort with lower power to detect significance was used.  This means that significant 
associations could have been missed.  Nonetheless, this pilot study validated the 
bioinformatic results of the first part of the study.  An additional limitation included the tools 
used for bioinformatic analyses.  Many of these tools are still in the development phase and 
therefore significant associations could have been missed.  Additionally, due to 
inconsistencies between these bioinformatic tools (as demonstrated by the different genes 
predicted to be affected by RegulomeDB and rSNPBase) numerous tools needed to be used.   
 
5.2 FUTURE DIRECTIONS 
Future work would include optimization of bioinformatics pipelines for the analysis of non-
coding regions.  In fact, new programs are being developed and made publically available at 
a rapid pace, with many of the programs used in this study having being developed within the 
last three years.  It is expected that with the progress of projects such as ENCODE and 
FANTOM, the programs that utilize these databases will also improve, thereby increasing the 
reliability of the results.  Furthermore, the bioinformatic results of this study will be validated 
in a larger South African Xhosa cohort.  Custom TaqMan® OpenArray® Genotyping Plates 
were designed to genotype more of the regulatory variants identified in this study in a larger 
cohort of Xhosa individuals.  The genotyping is currently being done and it is hoped that the 
findings would provide valuable information regarding schizophrenia susceptibility in this 
population.  However, validation of these results will also be required in other populations, 
due to the differences in population genetics as demonstrated in this study.  Regarding the 
Stellenbosch University  http://scholar.sun.ac.za
CHAPTER 5  CONCLUSION & FUTURE DIRECTIONS 
82 
 
inclusion of African populations in large scale studies, it is crucial that the various African 
populations be included in GWAS studies, particularly when focussing on complex 
phenotypes.  These populations provide valuable, genetically unique information that could 
aid in uncovering the intricate genetic architectures of many complex diseases.  Furthermore, 
an advantage of including individuals from these populations is that the LD patterns observed 
in their genomes differ significantly.  The wealth of genetic variation due to the multitude of 
ethnic groups should be explored for the enhancement of future studies.  The 1000 Genomes 
Project is in fact already involved in resequencing 100 individuals from each of the following 
five countries: Malawi, Kenya, Gambia, Nigeria and Sierra Leone (The 1000 Genomes 
Project Consortium, 2014).  Though this will inevitably aid in understanding the genetic 
diversity of African individuals, it would still be crucial for individuals of populations from 
different regions of Africa to be included in large scale disease studies in the future.  There 
can be no hope of alleviating the burden of crippling disorders on individuals from Africa 
without acknowledging the contribution that these individuals could make to future research 
efforts with regards to genetic information.   
In conclusion, this study met the aims and objectives set out at the beginning.  The major goal 
of personalized medicine is not only to determine optimal medication based on an 
individual’s unique genetic architecture, but more importantly to be able to predict an 
individual’s risk for an illness and achieve an accurate diagnosis (Ozomaro et al., 2013).  
Difficulties in studying schizophrenia and risk for this disorder have mainly been due to the 
heterogeneity of the disorder, interactions between genetic and environmental factors, side 
effects of prescribed medication and disease stage (Tomasik et al., 2014).  However, novel 
approaches as used in this study could provide a new perspective and potentially be more 
fruitful.  It is hoped that the findings of this study will stimulate future research studies, 
thereby contributing to the understanding of the genetic factors that are involved in 
schizophrenia susceptibility in order to alleviate the burden of this disorder.  
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APPENDIX 1:  Conference presentations and Academic Exchanges 
 
Conference Poster Presentations 
 M. Coffee, N. Ishaque, B.I. Drögemöller, D.J.H. Niehaus, L. Warnich. 2013. “Linking 
gene regulation and schizophrenia susceptibility variants: insights into novel 
treatment strategies”. 17
th
 World Congress of Basic & Clinical Pharmacology (WCP), 
Cape Town, South Africa. 
 
Academic Exchanges 
 August – November 2013:  DAAD Award for a Short-term Research Scholarship (4 
months) tenable at a German University (within the DAAD-NRF In-Country 
Scholarship Programme).  Visit completed at the Division of Theoretical 
Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.  
Supervised by Dr. Naveed Ishaque.   
 February – May 2014:  A*STAR SIPGA Award for a 3 month exchange in 
Singapore.  Completed at the Biomolecular Function Discovery Division, 
Bioinformatics Institute, Singapore.  Supervised by Dr Birgit Eisenhaber. 
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APPENDIX 2:  Scripts used for bioinformatics analysis 
weave_fasta_for_sTRAP.pl  
Written by Dr Naveed Ishaque 
# use strict; 
my $usage = "This program weaves fasta files for sTRAP\n\n\t$0 
[dbSNP bed file, 4th col = ref, 5th col = alt] [PRE FASTA] [POST 
FASTA]\n\n"; 
my $nex  = shift or die "Please provide SNP CSV file\n\n$usage"; 
my $pre  = shift or die "Please provide PRE FASTA 
file\n\n$usage"; 
my $post = shift or die "Please provide POST FASTA 
file\n\n$usage"; 
open (NEX_F, "$nex") or die "Cannot open NEXUS FILE 
'$nex'\n\n$usage"; 
open (PRE_F, "$pre") or die "Cannot open PRE FASTA FILE 
'$nex'\n\n$usage"; 
open (POST_F, "$post") or die "Cannot open POST FASTA FILE 
'$nex'\n\n$usage"; 
 
my %iupac=("B" => ["C","G","T"], "D" => ["A","G","T"], "K" => 
["G","T"], "M" => ["A","C"], "R" => ["A","G"], "S" => ["C","G"], "V" 
=> ["A","C","G"], "W" => ["A","T"], "Y" => ["C","T"]); 
 
while (<NEX_F>){if (/^(.*?)\t(.*?)\t(.*?)\t(.*?)\t(.*?)\t(.*?)$/){my 
($snp, $ref, $alt) = ($4,$5,$6); 
    my $pre_f_line= <PRE_F>; 
    $pre_f_line= <PRE_F>;    
    my $post_f_line= <POST_F>; 
    $post_f_line= <POST_F>; 
    chomp ($pre_f_line); 
    chomp ($post_f_line); 
    if ($alt =~ m/A/ || $alt =~ m/C/ ||$alt =~ m/G/ ||$alt =~ m/T/ ) 
{ 
      print ">$snp"."_WT\n$pre_f_line$ref$post_f_line\n"; 
      print ">$snp"."_MUT\n$pre_f_line$alt$post_f_line\n"; 
    } 
    else {  
      #my @bases=$iupac{$alt}; 
      foreach my $base (@{$iupac{$alt}}){ 
#        warn "$snp $alt $base\n"; 
        print 
">$snp"."_$alt$base"."_WT\n$pre_f_line$ref$post_f_line\n"; 
        print 
">$snp"."_$alt$base"."_MUT\n$pre_f_line$base$post_f_line\n"; 
      }    }  } 
  else { 
    die "invalid line in SNP NEXUS file: $_\n"; 
  } 
} 
close (NEX_F); close (PRE_F); close (POST_F); 
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APPENDIX 3:  Supplementary Material – Bioinformatics Results 
Table S1.  Most significant SNPs from previous GWAS 
SNP 
RS NUMBER 








rs2523722 6 MHC, TRIM26 
1606 European cases, 
1794 European controls 
13195 European cases, 
31021 European controls 
1.47E-16 1.25 Strange et al., 2012 
rs114002140 6 HLA-DRB9 
5001 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
9.14E-14 1.167 Ripke et al., 2013 
rs7085104 10 C10orf32-AS3MT 
5002 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
3.68E-13 1.11 Ripke et al., 2013 
rs6461049 7 MAD1L1 
5003 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
5.93E-13 1.107 Ripke et al., 2013 
rs6932590 6 PRSS16 
2,663 European cases, 
13,498 European 
controls 
10,282 European cases, 
21,093 European controls 
1.40E-12 1.16 
Stefansson et al., 
2009 
rs1198588 1 MIR137 
5004 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
1.72E-12 0.889 Ripke et al., 2013 
rs2021722 6 TRIM26 
9,394 European cases, 
12,462 European 
controls 
8,442 European cases, 
21,397 European controls 
2.18E-12 1.15 Ripke et al., 2011 
rs1006737 12 CACNA1C 
5005 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
5.22E-12 1.103 Ripke et al., 2013 
rs1635 6 NKAPL 
746 Han Chinese cases, 
1,599 Han Chinese 
controls 
4,027 Han Chinese cases, 
5,603 Han Chinese 
controls 
6.91E-12 0.78 Yue et al., 2011 
rs11038167 11 TSPAN18 
746 Han Chinese cases, 
1,599 Han Chinese 
controls 
4,027 Han Chinese cases, 
5,603 Han Chinese 
controls 
1.09E-11 1.29 Yue et al., 2011 
rs1625579 1 MIR137 
9,394 European cases, 
12,462 European 
controls 
8,442 European cases, 
21,397 European controls 
1.59E-11 1.12 Ripke et al., 2011 
rs835784 11 TSPAN18 
746 Han Chinese cases, 
1,599 Han Chinese 
4,027 Han Chinese cases, 
5,603 Han Chinese 
2.73E-11 1.27 Yue et al., 2011 
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rs17693963 6 MHC 
2111 European cases, 
2535 European controls 
11271 cases, 14601 
controls 
3.08E-11 1.24 Bergen et al., 2012 
rs13211507 6 PGBD1 
2,663 European cases, 
13,498 European 
controls 
10,282 European cases, 
21,093 European controls 
3.80E-11 1.24 
Stefansson et al., 
2009 
rs1233710 6 ZKSCAN4 
746 Han Chinese cases, 
1,599 Han Chinese 
controls 
4,027 Han Chinese cases, 
5,603 Han Chinese 
controls 
4.76E-11 0.79 Yue et al., 2011 
rs16887244 8 LSM1 
3,750 Han Chinese 
cases, 6,468 Han 
Chinese controls 
4,383 Han Chinese cases, 
4,539 Han Chinese 
controls 
1.27E-10 0.83 Shi et al., 2011 
rs17691888 10 CACNB2 
5006 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
1.27E-10 0.862 Ripke et al., 2013 
rs13219354 6 PRSS16 
2,663 European cases, 
13,498 European 
controls 
10,282 European cases, 
21,093 European controls 
1.30E-10 1.2 
Stefansson et al., 
2009 
rs4129585 8 TSNARE1 
5007 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
2.19E-10 1.091 Ripke et al., 2013 
rs3131296 6 HLA-E, NOTCH4 
2,663 European cases, 
13,498 European 
controls 
10,282 European cases, 
21,093 European controls 
2.30E-10 1.19 
Stefansson et al., 
2009 
rs12966547 18 CCDC68 
9394 European cases, 
12462 European 
controls 
8442 European cases, 
21397 European controls 
2.60E-10 1.09 Ripke et al., 2011 
rs10789369 1 x10NST00000415686.1 
5008 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
3.64E-10 1.095 Ripke et al., 2013 
rs2142731 6 PGBD1 
746 Han Chinese cases, 
1,599 Han Chinese 
controls 
4,027 Han Chinese cases, 
5,603 Han Chinese 
controls 
5.14E-10 0.79 Yue et al., 2011 
rs204999 6 MHC 
1606 European cases, 
1794 European controls 
13195 European cases, 
31021 European controls 
5.37E-10 1.33 Strange et al., 2012 
rs11038172 11 TSPAN18 
746 Han Chinese cases, 
1,599 Han Chinese 
controls 
4,027 Han Chinese cases, 
5,603 Han Chinese 
controls 
7.21E-10 1.25 Yue et al., 2011 
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rs6913660 6 HIST1H2BJ 
2,663 European cases, 
13,498 European 
controls 
10,282 European cases, 
21,093 European controls 
1.10E-09 1.15 
Stefansson et al., 
2009 
rs12666575 7 MAD1L1 
2111 European cases, 
2535 European controls 
11271 cases, 14601 
controls 
1.75E-09 0.89 Bergen et al., 2012 
rs7914558 10 CNNM2 
9394 European cases, 
12462 European 
controls 
8442 European cases, 
21397 European controls 
1.82E-09 1.1 Ripke et al., 2011 
rs7940866 11 SNX19 
5009 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
1.83E-09 0.921 Ripke et al., 2013 
rs2312147 2 VRK2 
7946 European cases, 
19 036 European 
controls 
9246 European cases, 22 
356 European controls 
1.90E-09 1.09 Steinberg et al., 2011 
rs12807809 11 NRGN 
2,663 European cases, 
13,498 European 
controls 
10,282 European cases, 
21,093 European controls 
2.40E-09 1.15 
Stefansson et al., 
2009 
rs17504622 5 ENST00000503048.1 
5010 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
2.65E-09 1.238 Ripke et al., 2013 
rs2905424 19 MAU2 
5011 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
3.44E-09 1.092 Ripke et al., 2013 
rs11819869 11 AMBRA1 
1169 European cases, 
European controls 3714 
2569 European cases, 
4088 European controls 
3.89E-09 1.25 Rietschel et al., 2012 
rs9960767 18 TCF4 
2,663 European cases, 
13,498 European 
controls 
10,282 European cases, 
21,093 European controls 
4.10E-09 1.23 
Stefansson et al., 
2009 
rs1488935 8 WHSC1L1 
3,750 Han Chinese 
cases, 6,468 Han 
Chinese controls 
4,383 Han Chinese cases, 
4,539 Han Chinese 
controls 
5.06E-09 0.87 Shi et al., 2011 
rs7527939 1 HHAT 
188 European cases, 
376 European controls 
99 European cases, 328 
European controls 
6.49E-09 2.63 Betcheva et al., 2013 
rs2373000 2 QPCT 
5012 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
6.78E-09 1.087 Ripke et al., 2013 
rs4309482 18 TCF4 
7946 European cases, 
19 036 European 
controls 
9246 European cases, 22 
356 European controls 
7.80E-09 1.09 Steinberg et al., 2011 
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rs6878284 5 SLCO6A1 
5013 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
9.03E-09 0.92 Ripke et al., 2013 
rs10489202 1 BRP44 
3750 Han Chinese 
cases, 6468 Han 
Chinese controls 
4383 Han Chinese cases, 
4539 Han Chinese 
controls 
9.50E-09 1.19 Shi et al., 2011 
rs13194053 6 HIST1H2BJ 
2,681 European cases, 
2,653 European 
controls, 1,286 African 
American cases, 973 
African American 
controls 
5,327 European cases, 
16,424 European controls 
9.54E-09 0.88 Shi et al., 2009 
rs11191580 10 NT5C2 
9,394 European cases, 
12,462 European 
controls 
8,442 European cases, 
21,397 European controls 
1.11E-08 1.15 Ripke et al., 2011 
rs4687552 3 ITIH3 
5014 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
1.16E-08 1.086 Ripke et al., 2013 
rs12991836 2 ZEB2 
5015 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
1.19E-08 0.922 Ripke et al., 2013 
rs2949006 2 FONG 
5016 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
1.21E-08 1.102 Ripke et al., 2013 
rs4801131 18 ENST00000565991.1 
5017 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
1.22E-08 0.925 Ripke et al., 2013 
rs7004633 8 MMP16 
9,394 European cases, 
12,462 European 
controls 
8,442 European cases, 
21,397 European controls 
1.45E-08 1.16 Ripke et al., 2011 
rs778371 2 C2orf82 
5018 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
1.51E-08 0.92 Ripke et al., 2013 
rs14403 1 AKT3 
5019 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
1.80E-08 0.91 Ripke et al., 2013 
rs11532322 12 C12orf65 
5020 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
2.28E-08 1.094 Ripke et al., 2013 
rs17512836 18 TCF4 
9,394 European cases, 
12,462 European 
controls 
8,442 European cases, 
21,397 European controls 
2.35E-08 1.4 Ripke et al., 2011 
rs1538774 1 SDCCAG8 5021 Swedish cases, 7,452 cases, 20,404 2.53E-08 0.917 Ripke et al., 2013 
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6243 Swedish controls controls and 581 trios 
rs11098403 4 NDST3 
904 Askenazi Jewish 
cases, 1640 Ashkenazi 
Jewsih controls 
10200 mixed population 
cases, 12991 mixed 
population controls 
2.67E-08 1.15 Lencz et al., 2013 
rs548181 11 STT3A 
9,394 European cases, 
12,462 European 
controls 
8,442 European cases, 
21,397 European controls 
2.91E-08 1.2 Ripke et al., 2011 
rs11995572 8 Intergenic 
5022 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
3.33E-08 1.12 Ripke et al., 2013 
rs171748 5 ENST00000506902.1 
5023 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
3.78E-08 1.078 Ripke et al., 2013 
rs7709645 5 ZSWIM6 
2111 European cases, 
2535 European controls 
11271 cases, 14601 
controls 
3.80E-08 1.11 Bergen et al., 2012 
rs3800316 6 unknown 
2,681 European cases, 
2,653 European 
controls, 1,286 African 
American cases, 973 
African American 
controls 
5,327 European cases, 
16,424 European controls 
3.81E-08 0.86 Shi et al., 2009 
rs2910032 5 - 
5024 Swedish cases, 
6243 Swedish controls 
7,452 cases, 20,404 
controls and 581 trios 
4.12E-08 0.925 Ripke et al., 2013 
rs10503253 8 CSMD1 
9,394 European cases, 
12,462 European 
controls 
8,442 European cases, 
21,397 European controls 
4.14E-08 1.11 Ripke et al., 2011 
rs3800307 6 unknown 
2,681 European cases, 
2,653 European 
controls, 1,286 African 
American cases, 973 
African American 
controls 
5,327 European cases, 
16,424 European controls 
4.35E-08 0.89 Shi et al., 2009 
rs886424 6 MHC 
2111 European cases, 
2535 European controls 
11271 cases, 14601 
controls 
4.54E-08 0.71 Bergen et al., 2012 
rs17662626 2 PCGEM1 
9,394 European cases, 
12,462 European 
controls 
8,442 European cases, 
21,397 European controls 
4.65E-08 1.2 Ripke et al., 2011 
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Table S2.  SNPs in regulatory regions (with a RegulomeDB score between 1a and 
3b) 
SNP Score SNP Score SNP Score SNP Score 
rs200981 1a rs2916074 1f rs2297787 2a rs1233583 2b 
rs886424 1b rs2523722 1f rs200949 2a rs4129585 2c 
rs4808967 1b rs2523719 1f rs938575 2b rs926300 3a 
rs4808203 1b rs2517612 1f rs9324383 2b rs7709645 3a 
rs2535629 1b rs2517611 1f rs876701 2b rs718885 3a 
rs200485 1b rs2297786 1f rs7921574 2b rs71559051 3a 
rs16887343 1b rs2071278 1f rs761171 2b rs7067970 3a 
rs3094071 1d rs200995 1f rs7527939 2b rs67457459 3a 
rs200483 1d rs200954 1f rs67340775 2b rs59498392 3a 
rs1059612 1d rs200948 1f rs61882678 2b rs56401801 3a 
rs9633712 1e rs200484 1f rs60935759 2b rs13197175 3a 
rs943037 1f rs1926032 1f rs55703821 2b rs55657382 3a 
rs9262143 1f rs17115213 1f rs4537271 2b rs4656564 3a 
rs9262141 1f rs16887244 1f rs433061 2b rs35909544 3a 
rs911186 1f rs1264361 1f rs425335 2b rs35744819 3a 
rs886422 1f rs1264350 1f rs401754 2b rs35525740 3a 
rs7745603 1f rs1264322 1f rs3800913 2b rs34218844 3a 
rs736408 1f rs1264304 1f rs3779921 2b rs3094072 3a 
rs7125907 1f rs12413046 1f rs3765879 2b rs3094070 3a 
rs6996860 1f rs12412038 1f rs3765872 2b rs28681082 3a 
rs6913660 1f rs11777067 1f rs3740400 2b rs28360499 3a 
rs6904596 1f rs4428528 1f rs35202262 2b rs2747054 3a 
rs4808964 1f rs1150752 1f rs34765154 2b rs2717007 3a 
rs4808200 1f rs7766843 1f rs34064842 2b rs2678903 3a 
rs4409766 1f rs4434496 1f rs3129984 2b rs2142731 3a 
rs3794993 1f rs11191582 1f rs3129697 2b rs200489 3a 
rs3781285 1f rs11191580 1f rs3095338 2b rs1371833 3a 
rs3134942 1f rs11191558 1f rs3006923 2b rs13219181 3a 
rs3132658 1f rs11191557 1f rs2905435 2b rs13199906 3a 
rs3131296 1f rs11191548 1f rs2270376 2b rs13197633 3a 
rs3131064 1f rs11191515 1f rs1846416 2b rs13197176 3a 
rs3131060 1f rs11191514 1f rs13262595 2b rs12272795 3a 
rs3130673 1f rs11191479 1f rs13212318 2b rs11783967 3a 
rs3130403 1f rs10883832 1f rs13199772 2b rs1233593 3a 
rs3129985 1f rs10883808 1f rs13195636 2b rs10786729 3a 
rs3129702 1f rs10748839 1f rs12221064 2b rs1060041 3a 
rs3129701 1f rs10748836 1f rs12219901 2b rs10100894 3a 
rs3095336 1f rs1049633 1f rs4280993 2b 
  rs3094629 1f rs4713074 2a rs1742743 2b 
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ER to Golgi transport vesicle membrane 8.38E-42 19 31 
ER to Golgi transport vesicle 5.13E-41 19 35 
lumenal side of membrane 5.13E-41 18 27 
integral component of lumenal side of 
endoplasmic reticulum membrane 
5.13E-41 18 27 
lumenal side of endoplasmic reticulum 
membrane 
5.13E-41 18 27 
transport vesicle membrane 1.83E-37 19 49 
antigen processing and presentation of 
exogenous peptide antigen 
2.89E-37 24 166 
antigen processing and presentation of 
exogenous antigen 
5.41E-37 24 171 
antigen processing and presentation of peptide 
antigen 
1.34E-36 24 178 
antigen processing and presentation 1.64E-34 24 216 
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Figure S1.  Full network analysis using GeneMANIA.  Query genes (which all mapped to 
specific pathways using DAVID) are indicated with black nodes.  Additional genes 
(identified by GeneMANIA), which are related to the query genes and fit to the implicated 
network, are indicated with grey nodes. 
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Figure S2.  The gene that had the highest score (80.32) in terms of associations with other 
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APPENDIX 4:  Supplementary Material – Association Study Results 
Comparison of minor allele frequencies between South African Xhosa cohort and YRI, CEU and CHB populations: 
 
Figure S3. Comparison of minor allele frequencies between the genotyped SNPs in the South African Xhosa cohort and the YRI, CEU and CHB 

































South African Xhosa Cases South African Xhosa Controls 1000 Genomes YRI HapMap YRI
1000 Genomes CHB HapMap CHB 1000 Genomes CEU HapMap CEU
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Figure S4. RFLP gel photos and corresponding chromatograms for each SNP: (a) rs200981 
(b) rs17693963 (c) rs13211507 (d) rs2535629 and (e) rs4687552. 
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Figure S4 (cont.). RFLP gel photos and corresponding chromatograms for each SNP: (f) 
rs200485 (g) rs200483 (h) rs3129701 (i) rs2517611 and (j) rs2021722. 
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0.0447 -0.59 -1.13 -0.05 
 
 
Table S5.  Reagents for RE digest of the PCR products (for RFLP analysis). (In all 








rs200981 5 0.9 - 
rs17693963 5 0.5 - 
rs13211507 5 0.3 0.2 
rs2535629 5 0.9 - 
rs4687552 5 0.8 - 
rs200485 5 0.8 - 
rs200483 5 0.9 - 
rs3129701 5 0.6 - 
rs2517611 5 0.9 - 
rs2021722 5 0.9 - 
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APPENDIX 5:  Protocols, Reagents And Solutions 
SureClean Quick-Clean Protocol (Bioline) 
 Add 1X volume of Quick-Clean to the PCR product . 
 Vortex. 
 Incubate at room temperature for 10 minutes. 
 Centrifuge at 13000 rpm for 10 minutes. 
 Discard supernatant. 
 Add 100 μl 70% ethanol. 
 Vortex for 30 seconds. 
 Centrifuge at 13000 rpm for 10 minutes. 
 Discard supernatant. 
 Air-dry. 
 Resuspend pellet in 10 μl water. 
 
Big Dye v3.1 Sequencing Chemistry (Applied Biosystems™) 
 Dilute PCR product according to the size of the template to be sequenced (Table S6). 
 In a 0.2 ml PCR tube, add 3 μl diluted PCR product, 3 μl diluted primer (3.3 ρmol), 
1.3 μl Big Dye reaction mix and 2.7 μl Half Dye mix. 
 Place the PCR tubes in a thermocycler with the following conditions: 
- 94ºC – 5 min 
- (94ºC – 10 sec, 55ºC – 10 sec, 60ºC – 4 min)    25X 
- 4ºC – ∞ 
 Add 1 μl 2.2% SDS to each tube and place the tubes in the thermocycler with the 
following conditions: 
- 98ºC = 5 min 
- 25ºC = 10 min 
 
Table S6.  Concentration of PCR product required 
according to template size being sequenced. 
Template Quantity 
PCR product:   
   100 – 200 bp 1 – 3 ng 
   200 – 500 bp 3 – 10 ng 
   500 – 1 000 bp 5 – 20 ng 
   1 000 – 2 000 bp 10 – 40 ng 
   >2 000 bp 20 – 50 ng 
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20X Stock (2 L) 
 90 g Boric Acid (61.83 g/mol) 
 16 g NaOH (40.00 g/mol) 
 BTV with dH2O 
1X SB 
 100 ml 20X SB 
 1900 ml  dH2O 
 
 
CRESOL LOADING DYE 
Stock 
 10 mg Cresol powder 
 1 ml dH2O 
Loading Dye 
 3.4 g Sucrose 
 200 μl Cresol Stock 
 9.5 ml dH2O 
 
GELS 
1.5% w/v Gel 
 1.5 g Agarose 
powder 
 100 ml 1X SB 
 5 μl Ethidium 
Bromide 
2% w/v Gel 
 2 g Agarose powder 
 100 ml 1X SB 
 5 μl Ethidium 
Bromide 
3% w/v Gel 
 3 g Agarose powder 
 100 ml 1X SB 
 5 μl Ethidium 
Bromide 
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